WO1997001331A2 - Method of producing sustained-release preparation - Google Patents

Method of producing sustained-release preparation Download PDF

Info

Publication number
WO1997001331A2
WO1997001331A2 PCT/JP1996/001770 JP9601770W WO9701331A2 WO 1997001331 A2 WO1997001331 A2 WO 1997001331A2 JP 9601770 W JP9601770 W JP 9601770W WO 9701331 A2 WO9701331 A2 WO 9701331A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
biodegradable polymer
metal salt
lactic acid
glycolic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1996/001770
Other languages
French (fr)
Other versions
WO1997001331A3 (en
Inventor
Kayoko Okamoto
Yutaka Yamagata
Yasutaka Igari
Masafumi Misaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to AU62420/96A priority Critical patent/AU6242096A/en
Priority to AT96921094T priority patent/ATE268591T1/en
Priority to EP96921094A priority patent/EP0835101B1/en
Priority to DE69632684T priority patent/DE69632684T2/en
Publication of WO1997001331A2 publication Critical patent/WO1997001331A2/en
Publication of WO1997001331A3 publication Critical patent/WO1997001331A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Definitions

  • the present invention relates to a sustained- release preparation comprising a biodegradable polymer metal salt and a bioactive polypeptide, and a method of producing thereof .
  • bioactive polypeptides or their derivatives exhibit a variety of pharmacologic activities in vivo. Some of these polypeptides have been produced on a large scale by utilizing Escherichia coli, yeasts, animal cells or host animals such as hamsters using recently developed genetic engineering and cell technology, and put to medicinal use.
  • these bioactive polypeptides must be frequently administered because of the generally short biological half-life. The repeated injections takes a significant physical burden on patients. To overcome this disadvantage, variou ⁇ attempts have been made to develop sustained-release preparations comprising bioactive polypeptides .
  • EP-461630 discloses prior art production technologies for sustained-release preparations designed for the enhanced efficiency of entrapment of water-soluble bioactive peptides . These preparations are obtained from an oil/water (o/w) emulsion comprising dissolving a water-soluble bioactive poly- peptide, a biodegradable polymer and a fatty acid salt in an organic solvent.
  • the present inventors made extensives investigations to resolve the above problems, and found that sustained-release preparations dispersing a bioactive polypeptide in an organic solvent containing a biodegradable polymer pre-converted to a metal salt, and subjecting the resulting dispersion to formulation have unexpected excellent properties such as a surprising enhancement of entrapment of bioactive polypeptides, suppression of initial burst of the polypeptides, constant long-term release, and so on.
  • the present invention has been developed after further elaborations based on the above findings.
  • the present invention is directed to:
  • a method of producing a sustained-release preparation which comprises dispersing a bioactive polypeptide in an organic solvent containing a biodegradable polymer metal salt, and subjecting the resulting dispersion to formation,
  • the metal salt is a polyvalent metal salt
  • the metal salt is selected from the group consisting of a zinc salt and a calcium salt
  • (21) a sustained-release preparation according to (19), wherein the concentration of the bioactive polypeptide is about 0.001 to about 30% (w/w), and (22) a sustained-release preparation according to (19), wherein the bioactive polypeptide is a growth hormone, and so on.
  • the biodegradable polymer of the present invention has low water soluability or is water-insoluble, and includes aliphatic polyesters, e.g., homopolymers or copolymers synthesized from one or more kinds of as- hydroxycarboxylic acids (e.g., glycolic acid, lactic acid, 2-hydroxybutyric acid, valinic acid, leucic acid, etc.), hydroxydicarboxylic acids (e.g., malic acid, etc.), hydroxytricarboxylic acids (e.g., citric acid, etc.), or their mixtures; poly- ⁇ -cyanoacrylic esters, e.g., poly(methyl ⁇ -cyanoacrylate) , poly(ethyl ⁇ - cyanoacrylate) , poly(butyl ⁇ -cyanoacrylate), etc.; and amino acid polymers, e.g., poly( ⁇ -benzyl-L-glutamate) etc . , or their mixtures .
  • the preferred biodegradable polymers are aliphatic polyesters, e.g., homopolymers or copolymers synthesized from one or more kinds of ⁇ - hydroxycarb ⁇ xylic acids (e.g., glycolic acid, lactic acid, 2-hydroxybutyric acid, etc.), hydroxydicarboxylic acids (e.g., malic acid, etc.) and hydroxytricarboxylic acids (e.g., citric acid, etc.), or their mixtures, and so on.
  • ⁇ - hydroxycarb ⁇ xylic acids e.g., glycolic acid, lactic acid, 2-hydroxybutyric acid, etc.
  • hydroxydicarboxylic acids e.g., malic acid, etc.
  • hydroxytricarboxylic acids e.g., citric acid, etc.
  • the homopolymers and copolymers synthesized from one or more kinds of the ⁇ -hydroxycarboxylic acids are preferable in view of biodegradability and biocompatibility.
  • Particularly preferred aliphatic polyesters are copolymers synthesized from two or more kinds of the ⁇ -hydroxycarboxylic acids. Furthermore, these copolymers can be used as mixtures.
  • the ⁇ -hydroxycarboxylic acids are chiral compounds, they may be any of D-, L- and D-, L- configuration. It is preferable that the ratio of the D-/L-configuration (mol %) is in the range of about 75/25 to about 25/75. More preferred is a hydroxycarboxylic acid wherein the ratio of the D-/L- configuration (mol %) is in the range of about 60/40 to about 30/70.
  • polylactic acid a lactic acid polymer (hereinafter sometimes referred to as "polylactic acid”) .
  • the ⁇ -hydroxycarboxylic acid copolymer includes copolymers of glycolic acid with the other ⁇ - hydroxycarboxylic acids such as lactic acid and 2- hydroxybutyric acid.
  • Preferred ⁇ -hydroxycarboxylic acid copolymers are lactic acid-glycolic acid copolymer and 2- hydroxybutyric acid-glycolic acid copolymer.
  • a particularly preferred ⁇ -hydroxycarboxylic acid copolymer is a lactic acid-glycolic acid copolymer.
  • the polylactic acid may be either D-configuration or L-configuration or a mixture; one with the D-/L- configuration ratio (mol %) of about 75/25 to about 20/80 is preferred. More preferred is a polylactic acid wherein the ratio of the D-/L-configuration (mol %) is in the range of about 60/40 to about 25/75. Most preferred is a polylactic acid wherein the ratio of D- /L-configuration is in the range of about 55/45 to about 25/75.
  • the polylactic acid preferably has the weight average molecular weight, as defined below, of about 1,500 to about 10,000. More preferred is a polylactic acid having the weight average molecular weight of about 2,000 to about 8,000. Particularly preferred is a polylactic acid having the weight average molecular weight of about 3,000 to about 6,000.
  • the dispersity (weight average molecular weight/number average molecular weight) of polylactic acid is preferably in the range of about 1.2 to about 4.0, and more preferably in the range of about 1.5 to about 3.5.
  • the polylactic acid can be produced by the prior art methods described in EP-172636 (e.g., by dehydrative polycondensation in the absence of a catalyst or by dehydrative polycondensation in the presence of an inorganic solid acid catalyst) .
  • the preferred polylactic acid is produced by dehydrative polycondensation in the absence of a catalyst.
  • the compositional ratio (lactic acid/glycolic acid, mol %) in the lactic acid-glycolic acid copolymer is preferably about 100/0 to about 40/60, more preferably about 90/10 to about 45/55, and most preferably about 60/40 to about 40/60.
  • the weight average molecular weight of the lactic acid-glycolic acid copolymer is preferably about 3,000 to about 20,000, and more preferably about 4,000 to about 15,000.
  • the dispersity (weight average molecular weight/number average molecular weight) of the lactic acid-glycolic acid copolymer is preferably about 1.2 to about 4.0, and more preferably about 1.5 to about 3.5.
  • the lactic acid-glycolic acid copolymers can be produced by the known methods described in EP-172636 (e.g., dehydrative polycondensation in the absence of a catalyst or dehydrative polycondensation in the presence of an inorganic solid acid catalyst) .
  • the preferred copolymer is one produced by dehydrative polycondensation in the absence of a catalyst.
  • two kinds of lactic acid-glycolic acid copolymers differing in compositional ratio and weight average molecular weight can be used in an admixture of any ratio.
  • the typical example is a mixture of a lactic acid-glycolic acid copolymer wherein the compositional ratio of the lactic acid/glycolic acid (mol %) is about 75/25 and the weight average molecular weight is about 6,000.
  • Another example is lactic acid-glycolic acid copolymer wherein the compositional ratio of the lactic acid/glycolic acid (mol %) is about 50/50 and the weight average molecular weight is about 4,000.
  • the preferred weight ratio of the mixture is about 25/75 to about 75/25.
  • the compositional ratio of the 2-hydroxybutyric acid-glycolic acid copolymer is about 10 to about 75 mol % of glycolic acid and the remaining mol % of 2- hydroxybutyric acid, more preferably about 20 to about 75 mol % of glycolic acid, and more preferably about 30 to about 70 mol % of glycolic acid.
  • the weight average molecular weight of 2-hydroxybutyric acid-glycolic acid copolymer is preferably about 2,000 to about 30,000, and more preferably about 3,000 to about 20,000.
  • the particularly preferred weight average molecular weight of the copolymer is about 4,000 to about 15,000.
  • the dispersity (weight average molecular weight/number average molecular weight) of 2-hydroxybutyric acid- glycolic acid copolymer is preferably about 1.2 to about 4.0, and more preferably about 1.5 to about 3.5.
  • 2-Hydroxybutyric acid-glycolic acid copolymers can be produced by the known methods described in EP-172636 (e.g., dehydrative polycondensation in the absence of a catalyst or dehydrative polycondensation in the presence of an inorganic solid acid catalyst) .
  • the preferred copolymer is one produced by dehydrative polycondensation in the absence of a catalyst.
  • glycolic acid copolymers e.g., lactic acid- glycolic acid copolymer, 2-hydroxybutyric acid-glycolic acid copolymer, etc.
  • the ratio of glycolic acid copolymer/polylactic acid may be, for example, about 10/90 to about 90/10.
  • the preferred ratio is about 20/80 to about 80/20, and the most preferred ratio is about 30/70 to about 70/30.
  • weight average molecular weight and number average molecular weight mean the polystyrene equivalent average molecular weight and number average molecular weight of a sample as determined by gel permeation chromatography (GPC) using 9 polystyrene standards having the weight average molecular weights of 120,000, 52,000, 22,000, 9,200, 5,050, 2,950, 1,050, 580 and 162. These determinations can be made using GPC Column KF804L x 2 (Showa Denko K. K.), RI Monitor L-3300 (Hitachi, Ltd.), and chloroform as the mobile phase.
  • GPC gel permeation chromatography
  • biodegradable polymers synthesized by the dehydrative polycondensation reaction in the absence of a catalyst have free carboxyl groups at the terminus.
  • Such biodegradable polymers having free carboxyl groups at the terminus feature a high correlation between the number average molecular weight determined by end-group titrimetric assay and the number average molecular weight determined by GPC assay using polystyrene standards of known molecular weights, as previously described.
  • the number average molecular weight can be determined in the following manner. About 1 g to 3 g of the biodegradable polymer is dissolved in a mixed solvent of acetone (25 ml) and methanol (5 ml), and the carboxyl groups in the solution are quickly titrated with 0.05N alcoholic potassium hydroxide solution using phenoiphthalein as indicator under stirring at room temperature (about 0 to about 30°C) .
  • the number average molecular weight is calculated by the following equation.
  • A the weight mass (g) of biodegradable polymer B: the amount (ml) of 0.05N alcoholic KOH solution added until end-point is reached
  • a biodegradable polymer having free carboxyl groups at the terminal which is synthesized from one or more kinds of ⁇ -hydroxy acids by dehydrative polycondensation in the absence of a catalyst, a high correlation is found between the number average molecular weight determined by GPC assay and the number average molecular weight determined by the end-group assay.
  • the number average molecular weight found by the end-group assay is considerably higher than the number average molecular weight found by GPC. Because of this difference, a biodegradable polymer having free carboxyl groups at the terminal can easily be differentiated from a biodegradable polymer not having free carboxyl groups at the terminus .
  • the number average molecular weight found by the end-group assay is an absolute value
  • the number average molecular weight found by GPC assay is a relative value dependent on many variables such as analytical methods and conditions (e.g., the types of mobile phase and column, reference standard, choice of slicing width, selection of baseline, etc.) and, therefore, is hard to generalize.
  • the preferred range is about 0.8 to about 1.5 times. That the number average molecular weight found by end-group assay is "considerably higher" than the number average molecular weight found by GPC means that the value found by the end-group assay is more than about twice the value found by the GPC assay.
  • the preferred polymers are those showing a high correlation between the number average molecular weight found by the end-group assay and the number average molecular weight found by the GPC assay.
  • the metal salts which can be used for converting a biodegradable polymer to its metal salt is not particularly limited as far as it does not exert bad influences in vivo.
  • the metal salt includes a salt formed by a monovalent metal such as alkali metals (e.g., sodium, potassium, etc.) or alkaline earth metals (e.g., calcium, magnesium, etc.), or a polyvalent metal such as zinc (II), iron (II, III), copper (II), tin (II, IV), and aluminum (II, III) with an inorganic acid or an organic acid.
  • a monovalent metal such as alkali metals (e.g., sodium, potassium, etc.) or alkaline earth metals (e.g., calcium, magnesium, etc.
  • a polyvalent metal such as zinc (II), iron (II, III), copper (II), tin (II, IV), and aluminum (II, III) with an inorganic acid or an organic acid.
  • the metal is preferably a polyvalent metal, and more preferably alkaline earth metals and zinc.
  • Particularly preferred metals are calcium and zinc.
  • Inorganic acids that may be used in the metal salt formation include hydrogen halide (e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, hydrofluoric acid), sulfuric acid, nitric acid, thiocyanic acid, and so on.
  • hydrogen halide e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, hydrofluoric acid
  • sulfuric acid nitric acid, thiocyanic acid, and so on.
  • Organic acids that may be used in the metal salt formation include aliphatic carboxylic acids and aromatic acids.
  • Preferred aliphatic carboxylic acid ⁇ are C j _ 9 aliphatic carboxylic acids, e.g., aliphatic monocarboxylic acids, aliphatic dicarboxylic acids, and aliphatic tricarboxylic acids.
  • the aliphatic carboxylic acids may be saturated or unsaturated.
  • the aliphatic monocarboxylic acids include C ⁇ g saturated aliphatic monocarboxylic acids (e.g., carbonic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthoic acid, caprylic acid, pelargonic acid, capric acid, etc.) and C 2 - 9 unsaturated aliphatic monocarboxylic acids (e.g., acrylic acid, propiolic acid, methacrylic acid, crotonic acid, isocrotonic acid, etc.).
  • saturated aliphatic monocarboxylic acids e.g., carbonic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthoic acid, caprylic acid, pelargonic acid, capric acid, etc.
  • C 2 - 9 unsaturated aliphatic monocarboxylic acids e.g., acrylic acid, propiolic acid, methacryl
  • the aliphatic dicarboxylic acids include C 2 _ 9 saturated aliphatic dicarboxylic acids (e.g., malonic acid, succinic acid, glutaric acid, adipic acid, pimellic acid, etc.) and C 2 _ 9 unsaturated aliphatic dicarboxylic acids (e.g., maleic acid, fumaric acid, citraconic acid, mesaconic acid, etc.).
  • C 2 _ 9 saturated aliphatic dicarboxylic acids e.g., malonic acid, succinic acid, glutaric acid, adipic acid, pimellic acid, etc.
  • C 2 _ 9 unsaturated aliphatic dicarboxylic acids e.g., maleic acid, fumaric acid, citraconic acid, mesaconic acid, etc.
  • the aliphatic tricarboxylic acids include C 2 _ 9 saturated aliphatic tricarboxylic acids (e.g., tri- carvallylic acid, 1,2 ,3-butanetricarboxylic acid, etc. ) .
  • aliphatic carboxylic acids additionally may have 1 or 2 hydroxyl groups.
  • Illustrative examples are glycolic acid, lactic acid, glyceric acid, tartronic acid, malic acid, tartaric acid, citric acid, and so on.
  • Preferred aliphatic carboxylic acids are aliphatic monocarboxylic acids. More preferred aliphatic carboxylic acids are C 2 _ 9 aliphatic monocarboxylic acids. Particularly preferred are C 2 _ 3 saturated aliphatic monocarboxylic acids. The most preferred aliphatic carboxylic acid includes acetic acid.
  • Aromatic acids that may be used in the metal salt formation include benzoic acid, salicylic acid and phenolsulfonic acid.
  • the metal salt of the biodegradable polymer may also be obtained using the acetylacetonate or oxide of the above-mentioned polyvalent metals.
  • Preferred metal donors of the type are zinc acetylacetonate and zinc oxide.
  • Metal salts which can be used for converting a biodegradable polymer to its metal salt are preferably the salt formed by a polyvalent metals with an organic or inorganic acid (hereinafter referred to as a polyvalent metal salt) .
  • Polyvalent metal salt that may be used include salts of zinc with an inorganic acid, e.g., zinc halides (e.g. zinc chloride, zinc bromide, zinc iodide, zinc fluoride), zinc sulfate, zinc nitrate, zinc thiocyanate, etc.; salts of zinc with an organic acid, e.g., aliphatic carboxylic acid zinc salts (e.g. zinc carbonate, zinc acetate, zinc glycolate, zinc lactate, zinc tartrate, etc.), aromatic zinc salts (e.g.
  • an inorganic acid e.g., zinc halides (e.g. zinc chloride, zinc bromide, zinc iodide, zinc fluoride), zinc sulfate, zinc nitrate, zinc thiocyanate, etc.
  • salts of zinc with an organic acid e.g., aliphatic carboxylic acid zinc salts (e.g. zinc carbonate, zinc acetate, zinc glycolate, zinc
  • salts of calcium with an inorganic acid e.g., calcium halide (e.g., calcium chloride, calcium bromide, calcium iodide, calcium fluoride, etc.), calcium sulfate, calcium nitrate, calcium thiocyanate, etc.; salts of calcium with an organic acid, e.g., aliphatic carboxylic acid calcium salt (e.g, calcium carbonate, calcium acetate, calcium propionate, calcium oxalate, calcium tartrate, calcium lactate, calcium citrate, calcium gluconate, etc.) and aromatic calcium salts (e.g. calcium benzoate, calcium salicylate, etc.).
  • an organic acid e.g., aliphatic carboxylic acid calcium salt (e.g, calcium carbonate, calcium acetate, calcium propionate, calcium oxalate, calcium tartrate, calcium lactate, calcium citrate, calcium gluconate, etc.) and aromatic calcium salts (e.g. calcium benzoate, calcium salicy
  • the preferred polyvalent metal salt includes zinc acetate and calcium acetate.
  • the bioactive polypeptides used in the present invention include bioactive polypeptides having molecular weights from about 1,000 to about 50,000, preferably about 5,000 to about 40,000.
  • the representative activity of the bioactive peptide in the present invention is hormonal activity.
  • the bioactive polypeptides may be natural products. synthetic products, semi-synthetic products, and their derivatives .
  • the mode of action of the bioactive polypeptide may be agonistic or antagonistic.
  • the bioactive polypeptide for use in the present invention includes peptide hormones, cytokines, hematopoietic factors, various growth factors and enzymes .
  • the bioactive polypeptide hormones include insulin, growth hormone, naturiuretic peptides, gastrin, prolactin, adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), luteinizing hormone (LH) , follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG) and motilin.
  • the preferred hormones are insulin and growth hormone.
  • the bioactive polypeptide cytokines include lymphokines and monokines .
  • the lymphokines includes interferons (alpha, beta and gamma) and interleukins (IL-2 to IL-12).
  • the monokines includes interleukin-1 (IL-1), and tumor necrosis factor.
  • the preferred cytokine is a lymphokine and, more preferred interferon.
  • the particularly preferred cytokine is interferon- ⁇ .
  • the bioactive polypeptide hematopoietic factors include erythropoietin, granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), thrombopoietin, platelet-derived growth factor, and megakaryocyte potentiator.
  • the bioactive polypeptide growth factors include basic and acidic fibroblast growth factors (FGF) and their families (e.g., FGF-9), nerve growth factor (NGF) and it ⁇ family, in ⁇ ulin-like growth factors (e.g. IGF- 1, IGF-2, etc.) and bone morphogenetic protein (BMP) and family.
  • FGF basic and acidic fibroblast growth factors
  • NGF nerve growth factor
  • BMP bone morphogenetic protein
  • the bioactive polypeptide enzymes include superoxide dismutase (SOD), tissue plasminogen activator (TPA) and kallikrein.
  • SOD superoxide dismutase
  • TPA tissue plasminogen activator
  • kallikrein kallikrein.
  • the metal content of the bioactive polypeptide in the present invention is preferably not greater than 0.1%, more preferably not greater than 0.01%, and most preferably not greater than 0.001%.
  • substan ⁇ tially metal-free bioactive polypeptides are most suited for the present invention.
  • Crystalline insulin for instance, usually contains small amounts of heavy metals such as zinc, nickel, cobalt and cadmium. Insulin containing 0.4% (w/w) zinc exists as a stable hexamer and appears to be relatively inert in the interaction with the biodegradable polymer metal salt.
  • the metals occurring in the bio ⁇ active polypeptide may be previously removed from the polypeptide by known methods.
  • one known method comprises dialyzing an aqueous hydrochlonic acid solution of insulin against water or an aqueous solution of ammonium acetate and lyophilizing the dialysate to provide amorphous insulin with minimal metal content.
  • the biodegradable polymer metal salt in the present invention can be produced by emulsifing and dispersing an aqueous solution or solid form of a metal salt in an organic solvent solution of a biodegradable polymer to prepare a water/oil (w/o) or oil/water (o/w) emulsion or an organic solution or suspension of a biodegradable polymer containing a metal salt.
  • the resulting substances are washed and dried or subjected to an in-water drying method, phase separation method, spray drying method or the like with washing and drying.
  • the metal salt which does not participate in the formation of a salt with the biodegradable polymer in this process is preferably removed.
  • the organic solvent mentioned above preferably has a boiling point not exceeding 120°C.
  • Such organic solvent includes halogenated hydrocarbon ⁇ (e.g., dichloromethane, chloroform, carbon tetrachloride, etc.), alcohols (e.g. ethanol, methanol, etc.), acetonitrile, and so on. These solvents can also be used as a mixture.
  • the preferred organic solvents are dichloromethane and acetonitrile. Particularly preferred is dichloromethane.
  • the metal content of the biodegradable polymer metal salt is preferably about 0.01 to about 10% (w/w), more preferably about 0.05 to about 7% (w/w), and most preferably about 0.1 to about 5% (w/w).
  • the metal content of a biodegradable polymer metal salt can be determined by atomic absorption spectrometry.
  • the biodegradable polymer i ⁇ fir ⁇ t dissolved in an organic solvent to prepare an organic ⁇ olvent ⁇ olution (hereinafter referred to sometime ⁇ as the oil phase) .
  • the concentration of the biodegradable polymer in this organic solvent solution is suitably selected according to the molecular weight of the polymer and the kind of organic solvent used.
  • the concentration of the biodegradabe polymer in the organic ⁇ olvent may be about 0.01 to about 90% (w/w), preferably about 0.1 to about 80% (w/w), and more preferably about 1 to about 70% (w/w) .
  • an aqueou ⁇ solution of metal ⁇ alt ⁇ i ⁇ used for the internal aqueous pha ⁇ e.
  • the metal salt concentration may be from about 10 to about 90% (w/v), and preferably about 20 to about 80% (w/v) . However, the metal salt concentration depends on the solubility of the metal salt in water.
  • the above metal salt aqueous solution is dispersed and emulsified in the organic ⁇ olvent solution of the biodegradable polymer to provide a w/o emulsion.
  • the volume ratio of the aqueous solution of metal salts in the organic solvent solution of the biodegradable polymer i ⁇ about 1:1,000 to about 1:1, preferably about 1:100 to about 1:2, and mo ⁇ t preferably about 1:50 to about 1:3.
  • Emulsification can be achieved by conventional emulsification methods such as by using a turbine mixer, a homogenizer or the like.
  • the w/o emulsion thus obtained is then added to an aqueous phase (the external aqueous phase) to give a w/o/w emulsion.
  • the oil-pha ⁇ e ⁇ olvent i ⁇ evaporated off to provide the desired biodegradable polymer metal salt.
  • the volume of the external aqueous pha ⁇ e may be ⁇ elected from the range of, for example, about 1 to about 10,000 times the volume of the oil phase.
  • the preferred range is about 2 to about 5,000 times, and the most preferred range is about 5 to about 2,000 times.
  • Solvent evaporation can be achieved by commonly used methods, including the method in which the ⁇ olvent is evaporated under normal or gradually reduced pressure while stirring using a propeller stirrer or a magnetic ⁇ tirrer, etc., and the method in which the solvent is evaporated while the degree of vacuum is adjusted using a rotary evaporator, and so on.
  • An emulsifier may be added to the external aqueou ⁇ pha ⁇ e.
  • the emul ⁇ ifier may be any substance capable of providing for stable w/o/w emulsion ⁇ .
  • examples of such emulsifiers include anionic surfactant ⁇ , nonionic surfactants, polyoxyethylene-castor oil derivative ⁇ , polyvinylpyrrolidone, polyvinyl alcohol, carboxymethylcellulose, lecithin, gelatin, hyaluronic acid and so on.
  • the preferred emulsifier is polyvinyl alcohol.
  • Multiple emulsifiers may also be used in combination for use in the external aqueou ⁇ pha ⁇ e.
  • the concentration of the emulsifier based on the external aqueous phase may be selected from the range of about 0.001 to about 20% (w/w).
  • the preferred range is about 0.01 to about 10% (w/w) and the still more preferred range is about 0.05 to about 5% (w/w).
  • a metal salt which is similar to or different from the metal salt contained in the internal aqueous phase may also be added to the external aqueous phase.
  • a fatty acid metal salt is added in such an amount that the concentration of the metal salt in the external aqueous phase is about 0.01 to 20% (w/w) or more preferably about 0.1 to 10% (w/w).
  • the biodegradable polymer metal salt thus produced is recovered by centrifugation or filtration, washed with distilled water several times to remove the emulsifier and other deposits from the salt surface, then redispersed in distilled water, and lyophilized.
  • B In-water drying method (o/w method)
  • the ratio of metal salt to biodegradable polymer is about 5:1 to about 1:100, preferably about 2 : 1 to about 1:50, and more preferably about 1: 1 to about 1:10.
  • the organic solvent solution thus obtained is then poured into an aqueous phase and an o/w emulsion i ⁇ prepared by using a turbine mixer or the like. Then, the oil-phase solvent is evaporated as in method (A) to provide the biodegradable polymer metal salt.
  • the volume of the aqueous phase is based on the volume of oil phase and is selected from the range of, for example, about 1 to about 10,000 times the volume of the oil phase, or preferably about 2 to about 5,000 times. The most preferred range is about 5 to about 2,000 times.
  • an emulsifier may be added into this aqueous phase.
  • a metal salt may be added into the aqueous pha ⁇ e that i ⁇ similar to or different from the metal salt which is added, and dispersed or dissolved in the oil phase.
  • the biodegradable polymer metal salt thus produced is separated, washed and lyophilized as in method (A) .
  • a coacervating agent is gradually added into the w/o emulsion a ⁇ used in method (A) or the organic solvent solution of biodegradable polymer containing the metal salt as used in method (B) under stirring to precipitate and solidify the biodegradable polymer metal salt.
  • the amount of coacervating agent used is based on the volume of the w/o emulsion or organic solvent solution of the biodegradable polymer.
  • the volume used is about 0.01 to about 1,000 time ⁇ the volume of the W/O emulsion or organic solution of the biodegradable polymer, preferably about 0.05 to about 500 times, and more preferably about 0.1 to about 200 times.
  • the coacervating agent may be a substance belonging to any of the categories of polymers, mineral oils or vegetable oils, which are mi ⁇ cible with the organic solvent used for dissolving the biodegradable polymer, but in which the biodegradable polymer is not appreciably soluble. Typical examples are silicone oil, sesame oil, soybean oil, corn oil, cottonseed oil, coconut oil, linseed oil, mineral oil, n-hexane, n- heptane, and so on.
  • the coacervating agents can be used in a combination of two or more kinds .
  • the biodegradable polymer metal salt thus produced is recovered by filtration and washed repeatedly with heptane or the like to remove the coacervating agent.
  • an antiflocculant may be added for preventing agglomeration of the particles.
  • Antiflocculants that may be used included a water-soluble polysaccharides, ⁇ uch a ⁇ mannitol, lacto ⁇ e, gluco ⁇ e, and ⁇ tarches (e.g. corn starch) , hyaluronic acid and its alkali metal salt, glycine, a protein such as fibrin, collagen and an inorganic salt such as sodium chloride, sodium hydrogen phosphate, and so on.
  • a biodegradable polymer metal ⁇ alt by thi ⁇ method either a w/o emulsion prepared from an aqueous solution of the metal salt and an organic solvent solution of the biodegradable polymer, or an organic solvent solution or suspen ⁇ ion of biodegradable polymer containing the metal salt, is ⁇ prayed via a nozzle into the drying chamber of a ⁇ pray drier to volatilize the organic solvent in fine droplet ⁇ in a very short time, and a fine biodegradable polymer metal salt is produced.
  • nozzle are a binary-fluid nozzle, a pressure nozzle and a rotary disk nozzle.
  • An aqueous solution of the above-described antiflocculant also may be sprayed via another nozzle in order to prevent agglomeration of biodegradable polymer metal salt with the w/o emulsion or the organic solvent solution or suspension of the biodegradable polymer containing the metal salt.
  • the biodegradable polymer metal salt thus produced is washed as in method (A) and, if necessary, further subjected to removal of water and organic solvent under heating and reduced pressure.
  • the sustained-release preparation of the present invention can be manufactured by dispersing a bioactive polypeptide in an organic solvent containing the bio ⁇ degradable polymer metal salt, and subjecting the resulting dispersion to formulation.
  • the manufacturing method of the present invention can be used with the above-described (A) in-water drying method (w/o/w method), (B) in-water drying method (o/w method), (C) phase separation method (coacervation method), (D) spray drying method, or any modification thereof.
  • the organic ⁇ olvent in the organic ⁇ olvent ⁇ olution i ⁇ preferably a ⁇ olvent with a boiling point not higher than 120°C.
  • Such organic solvent includes halogenated hydrocarbons (e.g., dichloromethane, chloroform, carbon tetrachloride, etc.), alcohols (e.g., ethanol, methanol, 1,4-butanediol, 1,5-pentanediol, etc.) and acetonitrile, among other ⁇ .
  • halogenated hydrocarbons e.g., dichloromethane, chloroform, carbon tetrachloride, etc.
  • alcohols e.g., ethanol, methanol, 1,4-butanediol, 1,5-pentanediol, etc.
  • acetonitrile among other ⁇ .
  • Any of the ⁇ olvents can be used together as a mixture.
  • dichloromethane or acetonitrile i ⁇ particularly preferred.
  • a combination of a halogenated hydrocarbon e.g., dichloromethane
  • acetonitrile or an alcohol e.g., methanol, ethanol, etc.
  • alcohol e.g., methanol, ethanol, etc.
  • the ratio (by volume) of the halogenated hydrocarbon to either acetonitrile or alcohol is about 40:1 to about 1:1 and preferably about 20:1 to about 1:1.
  • an organic solvent ⁇ olution of the biodegradable polymer metal ⁇ alt i ⁇ first prepared in the same manner as in method (A) de ⁇ cribed above.
  • concentration of the biodegradable polymer metal salt in the organic solvent ⁇ olution i ⁇ dependent on the type and molecular weight of biodegradable polymer metal ⁇ alt and the type of the organic solvent.
  • the ratio of biodegradable polymer metal salt to organic solvent may be about 0.01 to about 80% (w/w), and is preferably about 0.1 to about 70% (w/w), and most preferably about 1 to about 60% (w/w) .
  • an aqueou ⁇ solution of the bioactive polypeptide is used for the internal aqueous phase.
  • the concentration of the bioactive polypeptide in aqueous solution may be for example, about 0.1% (w/v) to about 500% (w/v), preferably about 1% (w/v) to about 400% (w/v) and more preferably about 10% (w/v) to about 300% (w/v) .
  • pH adjusting agent e.g., acetic acid, hydrochloric acid, sodium hydroxide, etc.
  • stabilizers e.g., serum albumin, gelatin, etc.
  • pre ⁇ ervative ⁇ e.g., p- hydroxybenzoic acid e ⁇ ter ⁇ , etc.
  • the ratio (v/v) of aqueous solution of bioactive polypeptide to organic solvent solution of biodegrad- able polymer metal salt is about 1:1,000 to about 1:1, preferably about 1:100 to about 1:5, and more preferably about 1:50 to about 1:5.
  • the w/o emulsion thus obtained is then poured in an aqueous phase (external aqueous phase) to give a w/o/w emulsion and the solvent in the oil phase is evaporated to provide microcapsules.
  • An emulsifier may be added to the external aqueous phase.
  • the emulsifier can be any substance that is generally capable of providing a stable w/o/w emulsion.
  • anionic surfactants nonionic surfactants, polyoxyethylene- castor oil derivatives, polyvinylpyrrolidone, polyvinyl alcohol, carboxymethylcellulose, lecithin, gelatin, hyaluronic acid, etc.
  • the preferred emulsifier is polyvinyl alcohol. Two or more kinds of emulsifiers can be used in combination.
  • the concentration of the emulsifier based on the external aqueous phase is chosen from a range of about 0.001%
  • a metal salt whether the same salt as that added to the internal aqueous phase or a different salt, can be added to the external aqueous phase.
  • a fatty acid metal salt is added so that the metal salt concentration of the external aqueous phase will be about 0.01% to about 20% (w/w) and preferably about 0.1% to about 10% (w/w).
  • the metal salt used in the internal aqueous phase can be prevented from migrating from the biodegradable polymer into the external aqueous phase.
  • the microcap ⁇ ules thus produced are recovered by centrifugation or filtration, washed with di ⁇ tilled water repeatedly to remove the emul ⁇ ifier and other deposits from the capsule surface, then redispersed in distilled water or the like, and lyophilized. Then, if nece ⁇ ary, residual water and organic solvent in the microcapsules are further removed by heating under reduced pres ⁇ ure.
  • the microcapsule ⁇ are heated at a temperature not below the glass transition temperature of the biodegradable polymer and not so high as to cause aggregation of the microcapsules .
  • the heating temperature is preferably selected within the range from the gla ⁇ transition temperature of the biodegradable polymer to about 30°C higher than the glass transition temperature of the biodegradable polymer.
  • glas ⁇ tran ⁇ ition temeraiture i ⁇ defined as the intermediate glas ⁇ transition temperature determined using a differential scanning calorimeter during heating at a rate of 10 or 20°C per minute.
  • an organic solvent solution of the biodegradable polymer metal salt is first prepared in the same manner as in method (A) .
  • the concentration of the biodegradable polymer metal salt in the organic solvent may be similar to that described in method (i) .
  • a bioactive polypeptide to prepare an organic solvent ⁇ olution or ⁇ u ⁇ pension containing the biodegradable polymer metal salt and bioactive polypeptide.
  • the weight ratio of the bioactive polypeptide to the biodegradable polymer metal salt may for example be about 1:1000 to about 1:1, preferably about 1:200 to about 1-5 and more preferably about 1:100 to about 1:5.
  • the solvent in the oil phase is then evaporated off to provide microcapsule ⁇ .
  • microcapsules thus obtained are recovered, washed and lyophilized as in method (i). Thereafter the microcap ⁇ ules may be heated under reduced pressure to remove the residual water and organic solvent as in method (i) .
  • phase separation method In the production of microcapsules by this method, a coacervating agent i ⁇ gradually added to the ⁇ ame w/o emul ⁇ ion a ⁇ used in method (i) or the same organic solvent solution of biodegradable polymer metal salt and bioactive polypeptide as used in method (ii) under stirring in the same manner a ⁇ in method (C) to afford precipitated and solidified microcapsules.
  • microcapsules thus produced are recovered and washed to remove the coacervating agent and free bioactive polypeptide as in method (C) . Then, if necessary, the residual water and organic solvent within the microcapsule ⁇ are removed by heating under reduced pressure in the same manner as in method (i).
  • an antiflocculant may be added for preventing agglomeration of particles as in method (C) .
  • the same w/o emulsion as used in method (i) or the same organic solvent solution containing the biodegradable polymer metal salt and bioactive polypeptide a ⁇ u ⁇ ed in method (ii) is sprayed via a nozzle in the same manner as in method (D) to provide microcapsules.
  • microcapsules thus obtained are heated under reduced pres ⁇ ure to remove residual water and organic solvent as in method (i).
  • the concentration of bioactive polypeptide comprised in the sustained-release preparation in the present invention is, for example, about 0.001 to about 30% (w/w), preferably about 0.02 to about 20% (w/w), more preferably about 0.1 to about 10% (w/w), and most preferably about 0.5 to about 5% (w/w).
  • the sustained-release preparation may be administered in the form of microcap ⁇ ule or in variou ⁇ dosage forms such as non-oral preparations (e.g., intramuscular-, subcutaneou ⁇ - or vi ⁇ ceral- injectable or indwellable preparation; nasal-, rectal or uterine- tran ⁇ muco ⁇ al preparation), or oral preparation ⁇ (e.g., cap ⁇ ule ⁇ ⁇ uch a ⁇ hard capsule and soft capsule, solid preparations such as in granules and powder, liquid preparations such as a suspension) .
  • non-oral preparations e.g., intramuscular-, subcutaneou ⁇ - or vi ⁇ ceral- injectable or indwellable preparation; nasal-, rectal or uterine- tran ⁇ muco ⁇ al preparation
  • oral preparation ⁇ e.g., cap ⁇ ule ⁇ ⁇ uch a ⁇ hard capsule and soft capsule, solid preparations such as in granules and powder, liquid preparations such as a suspension
  • the particularly preferred sustained-release preparation is by injection.
  • the microcapsule ⁇ may be formulated with a dispersant (e.g., surfactant ⁇ ⁇ uch a ⁇ Tween 80, HCO-60; poly ⁇ accharide ⁇ such as carboxymethylcellulose, sodium alginate, sodium hyaluronate; protamine ⁇ ulfate; polyethylene glycol 400, etc.), a pre ⁇ ervative (e.g., methyl paraben, propyl paraben, etc.), an i ⁇ otonizing agent (e.g., ⁇ odium chloride, mannitol, ⁇ orbitol, gluco ⁇ e, etc.), and a local anesthetic (e.g., xylocaine hydrochloride, chlorobutanol, etc.) to provide an aqueous suspen ⁇ ion, or di ⁇ per ⁇ ed with vegetable oil (e.g., ⁇ esame oil, corn oil
  • a dispersant e.
  • the microcapsules are preferably fine particle.
  • the size of microcap ⁇ ule ⁇ for an injectable ⁇ u ⁇ pension may be selected from the range satisfying the requirements for the degree of dispersion and passage through the needle used for the injection.
  • the microcapsul perticle size may be within the range of about 0.1 to about 300 ⁇ m, preferably about 1 to about 150 ⁇ m and more preferably about 2 to about 100 ⁇ m.
  • Methods of preparing microcapsules as a sterile preparation include, but are not limited to, the method in which the entire production process is sterile, the method in which gamma rays are used as the sterilant, and method in which an antiseptic is added during the manufacturing process.
  • the su ⁇ tained-relea ⁇ e preparation can be safely used in mammals (e.g., humans, bovine, swine, dogs, cats, mice, rats, rabbits, etc.) with low toxicity.
  • ⁇ ustained-release preparation is useful to prevent or treat diabetes when insulin is used as bioactive the polypeptide; growth hormone hyposecretion and Turner's syndrome when growth hormone is used; viral hepatiti ⁇ (e.g., type C hepatiti ⁇ , HBe antigen-po ⁇ itive active heptiti ⁇ ) and cancer (e.g., renal carcinoma, multiple myeloma, etc.) when interferon- ⁇ i ⁇ u ⁇ ed; anemia (e.g., anemia during a dialysis of kidney) when erythropoietin is used; neutropenia (e.g., in therapy of carcinostotic) and infections when G-CSF is used; cancer (e.g., hemangioendothelioma) when IL-2 i ⁇ u ⁇ ed; ga ⁇ trointestinal ulcer when FGF-9 is used; senile dementia and neuropathy when NGF is used; thrombosis when TPA is u
  • Dosage of the su ⁇ tained-release preparation is the effective concentration of the bioactive polypeptide in vivo, though the dosage varies with the type of the bioactive polypeptide, the desired duration of the release, the target di ⁇ ease, the subject animal species and the other factors .
  • the dosage of the bioactive polypeptide can be cho ⁇ en from the range of about 0.0001 to about 10 mg/kg body weight per an adult.
  • the more preferred dosage can be suitably chosen from the range of about 0.0005 to about 1 mg/kg body weight.
  • the preferred administration frequency of the sustained-release preparation may be suitably chosen from once a week to once every two weeks depending on the type of bioactive polypeptide, the dosage form, the duration of the release, the target disea ⁇ e, the subject animal species and other factors.
  • the dosage for an adult diabetic can be usually selected from the range of about 0.001 to about 1 mg (as active ingredient) /kg body weight and preferably from the range of about 0.01 to about 0.2 mg/kg body weight with the do ⁇ age form to be admini ⁇ tered on a weekly basis.
  • the do ⁇ age for a patient with pituitary dwarfi ⁇ m is chosen from the range of about 0.004 mg to about 4 mg/kg body weight and preferably about 0.04 mg to about 0.8 mg/kg body weight a ⁇ the active ingredient and i ⁇ preferably admini ⁇ tered at one-week intervals.
  • the dosage can be chosen from a range of about 0.008 mg to about 8 mg/kg body weight and preferably about 0.08 mg to about 1.6 mg/kg body weight, for administration every 2 weeks.
  • the ⁇ u ⁇ tained-relea ⁇ e preparation i ⁇ preferably ⁇ tored at room temperature or in the cold. More preferably, the sustained-relea ⁇ e preparation is ⁇ tored in the cold.
  • Room temperature mean ⁇ 15° to 25°C
  • cold mean ⁇ a temperature below 15°C.
  • aqueous zinc acetate solution 438 mg/ml aqueous zinc acetate solution and the mixture was agitated in a bench-top homogenizer to prepare a w/o emulsion.
  • This emulsion was poured into 800 ml of a 0.1% (w/v) aqueous polyvinyl alcohol (PVA) solution, the temperature of which was preadjusted to 18°C, and using a turbine homo-mixer, a w/o/w emulsion was prepared. Then, with this w/o/w emulsion being agitated at room temperature, the dichloromethane was evaporated off to produce a lactic acid-glycolic acid copolymer zinc salt.
  • PVA polyvinyl alcohol
  • This lactic acid-glycolic acid copolymer zinc salt was recovered by centrifugation (about 1000 rpm) and the supernatant was discarded. The pellet was wa ⁇ hed with 600 ml of di ⁇ tilled water twice and lyophilized to provide a powder of lactic acid-glycolic acid copolyme zinc salt.
  • Reference Example 4 1 g of recombinant human insulin (Wako Pure
  • TM of 6000 cut-off (Spectrapor 7 MWCO 1000, Spectrum Medical Industries, U.S.A.), the above solution was dialyzed again ⁇ t 10 L of 0.01N hydrogen chloride solution 3 times. The dialysate was further dialized against 30 L of 0.2M aqueous ammonium acetate solution once, 30 L of distilled water once and, then, lyophilized. The zinc content of the lyophilized insulin powder was les ⁇ than 0.0001% (w/w).
  • This emulsion was treated as in Reference Example 1 to provide a powdery lactic acid-glycolic acid copolymer zinc salt. As determined by atomic absorption spectrometry, the zinc content of this lactic acid-glycolic acid copolymer zinc salt was 1.15%.
  • This emul ⁇ ion was treated as in Reference Example 4 to provide a powdery lactic acid-glycolic acid copolymer zinc ⁇ alt. As determined by atomic absorption ⁇ pectro etry, the zinc content of this lactic acid-gly- colic acid copolymer zinc salt was 1.24%.
  • the dichloromethane ⁇ olvent wa ⁇ evaporated off to give a lactic acid- glycolic acid copolymer zinc salt.
  • This lactic acid— glycolic acid copolymer zinc ⁇ alt was harvested by centrifugation (about 1000 rpm) and the ⁇ upernatant wa ⁇ discarded.
  • the zinc content of this lactic acid- glycolic acid copolymer zinc salt was 1.19 % (w/w).
  • Example 1 900 mg of the lactic acid-glycolic acid copolymer zinc ⁇ alt obtained in Reference Example 1 was dis ⁇ olved in 1 ml of dichloromethane. To thi ⁇ ⁇ olution wa ⁇ added 100 mg of the lyophilized Zn-free in ⁇ ulin powder prepared in Reference Example 4 and the mixture wa ⁇ agitated in a bench-top homo-mixer to prepare an organic ⁇ olvent ⁇ olution containing both the in ⁇ ulin and the lactic acid-glycolic acid copolymer zinc salt.
  • PVA polyvinyl alcohol
  • Example 2 900 mg of the lactic acid-glycolic acid copolymer zinc salt prepared in Reference Example 2 was dissolved in 1 ml of dichloromethane. To this solution was added 100 mg of the lyophilized Zn-free insulin powder obtained in Reference Example 4 and the mixture was treated as in Example 1 to provide 450 mg of powdery insulin-containing microcapsule ⁇ .
  • Example 3 900 mg of the lactic acid-glycolic acid copolymer zinc salt prepared in Reference Example 3 was di ⁇ olved in 1.5 ml of dichloromethane. To thi ⁇ solution was added 100 mg of the lyophilized Zn-free in ⁇ ulin powder obtained in Reference Example 4 and the mixture was treated as in Example 1 to provide 503 mg of powdery insulin-containing microcapsules.
  • Example 5 950 mg of the lactic acid-glycolic acid copolymer zinc salt prepared in Reference Example 1 was dissolved in 1.5 ml of dichloromethane. To this solution was added the powder from 8 vials (128 IU) of human growth hormone (Genotropin 16IU/ampule, Sumitomo pharmaceutical Company Limited) and the mixture was treated as in Example 1 to provide 500 mg of growth hormone-containing microcapsules .
  • Example 5 950 mg of the lactic acid-glycolic acid copolymer zinc salt prepared in Reference Example 1 was dissolved in 1.5 ml of dichloromethane. To this solution was added the powder from 8 vials (128 IU) of human growth hormone (Genotropin 16IU/ampule, Sumitomo pharmaceutical Company Limited) and the mixture was treated as in Example 1 to provide 500 mg of growth hormone-containing microcapsules .
  • human growth hormone Genotropin 16IU/ampule, Sumitomo pharmaceutical Company Limited
  • the mixture was treated with a vortex mixer and, then, with a bench-top homogenizer to give an organic solvent solution containing both insulin and lactic acid-glycolic acid copolymer zinc salt.
  • This organic solvent solution was added to 2000 ml of a 0.1% (w/v) aqueous polyvinyl alcohol solution containing 1.4% of zinc acetate dihydrate preadjusted to 18°C, and using a turbine homomixer, an o/w emulsion was prepared. Then, while the o/w emulsion was agitated at room temperature, the dichloromethane was evaporated off to provide microcapsules. The microcapsules were harvested by centrifugation (about 1000 rpm) and the supernatant was discarded. The microcapsules were rinsed with 1200 ml of distilled water twice, and after addition of 250 mg of mannitol, they were lyophilized to provide 1.53 g of powdery insulin-containing microcapsules.
  • This organic ⁇ olvent solution was added to 1000 ml of a 0.1% (w/v) aqueous polyvinyl alcohol solution containing 0.7% (w/v) of zinc acetate dihydrate, which had been preadjusted to 18°C, and using a turbine homogenizer, an o/w emulsion was prepared. While the o/w emulsion was agitated at room temperature, the dichloromethane wa ⁇ evaporated off to provide microcap ⁇ ule ⁇ . The microcapsules were harvested by centrifugation (about 1000 rpm) and the supernatant wa ⁇ di ⁇ carded. The microcap ⁇ ule ⁇ were washed with 600 ml of di ⁇ tilled water twice, followed by addition of 100 mg of mannitol and lyophilization to provide 0.734 g of powdery insulin-containing microcapsules .
  • Example 1 147 mg of the insulin-containing microcapsules prepared in Example 1 was dispersed in 1.75 ml of dispersion medium (mannitol 5% (w/v), carboxymethylcellulose 0.5% (w/v), Tween 20 0.1% (w/v), adjusted to pH 6.8 with acetic acid). A 0.5 ml portion (insulin content 100 U) of this dispersion was injected subcultaneously at the back of streptozocin-induced hyperglycemic rats under ether anesthesia. Blood was serially drawn from the tail vein and the serum was separated. The concentration of insulin in each serum sample was determined by enzyme immunoassay using the two-antibody sandwich method.
  • dispersion medium mannitol 5% (w/v), carboxymethylcellulose 0.5% (w/v), Tween 20 0.1% (w/v)
  • a 0.5 ml portion (insulin content 100 U) of this dispersion was injected subcultaneously at the back of streptozocin-induced hyperglyce
  • Insulin Blood concentration prepa ⁇ ration 0.5 1 hr. 2 hr. 4 hr. 8 hr. 24 48 72 hr. hr. hr. hr.
  • Example 7 211 mg of the growth hormone-containing microcapsules obtained in Example 7 was dissolved in 1.75 ml of disper ⁇ ion medium. A 0.5 ml portion of this dispersion (containing 3 mg of growth hormone) was admini ⁇ tered subcutaneously at the back of ether- anesthetized rat ⁇ . Blood was drawn serially from the tail vein and the serum ⁇ eparated. The concentration of growth hormone in each serum ⁇ ample was determined by radioimmunoassay (Ab Bead HGH, Eiken Kagaku) . The results are presented in Table 2.
  • a sustained-release preparation with an enhanced rate of entrapment of bioactive polypeptides, inhibited early burst ⁇ of release after administration, and constant release kinetics over a long time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention provides a sustained-release preparation comprising a biodegradable polymer metal salt and bioactive polypeptide, with enhanced entrapment of the bioactive polypeptides, a suppression of initial burst, and a constant long-term release of the bioactive polypeptides.

Description

DESCRIPTION METHOD OF PRODUCING SUSTAINED-RELEASE PREPARATION
Technical Field The present invention relates to a sustained- release preparation comprising a biodegradable polymer metal salt and a bioactive polypeptide, and a method of producing thereof . Background Art It is known that bioactive polypeptides or their derivatives exhibit a variety of pharmacologic activities in vivo. Some of these polypeptides have been produced on a large scale by utilizing Escherichia coli, yeasts, animal cells or host animals such as hamsters using recently developed genetic engineering and cell technology, and put to medicinal use. However, these bioactive polypeptides must be frequently administered because of the generally short biological half-life. The repeated injections takes a significant physical burden on patients. To overcome this disadvantage, variouε attempts have been made to develop sustained-release preparations comprising bioactive polypeptides .
EP-461630 discloses prior art production technologies for sustained-release preparations designed for the enhanced efficiency of entrapment of water-soluble bioactive peptides . These preparations are obtained from an oil/water (o/w) emulsion comprising dissolving a water-soluble bioactive poly- peptide, a biodegradable polymer and a fatty acid salt in an organic solvent.
Although various attempts have been made to produce a sustained-release preparation retaining the bioactivity of bioactive polypeptides as mentioned above, there has not been a clinically satisfactory sustained-release preparation with efficiencient entrapment of a bioactive polypeptide into a biodegradable polymer, and suppression of initial drug burst, constant long-term drug release, and so on. Disclosure of Invention The present inventors made extensives investigations to resolve the above problems, and found that sustained-release preparations dispersing a bioactive polypeptide in an organic solvent containing a biodegradable polymer pre-converted to a metal salt, and subjecting the resulting dispersion to formulation have unexpected excellent properties such as a surprising enhancement of entrapment of bioactive polypeptides, suppression of initial burst of the polypeptides, constant long-term release, and so on. The present invention has been developed after further elaborations based on the above findings.
The present invention, therefore, is directed to:
(1) a method of producing a sustained-release preparation which comprises dispersing a bioactive polypeptide in an organic solvent containing a biodegradable polymer metal salt, and subjecting the resulting dispersion to formation,
(2) a method according to (1), wherein the metal salt is a polyvalent metal salt, (3) a method according to (1), wherein the metal salt is selected from the group consisting of a zinc salt and a calcium salt,
(4) a method according to (1), wherein the organic solvent is a mixture of halogenated hydrocarbons and acetonitrile or alcohols,
(5) a method according to (4), wherein the organic solvent mixture ratio of haloganated hydrocarbons to acetonitrile or alcohols is in the range of about 40:1 to about 1:1 (volume/volume), (6) a method according to (1), wherein the bioactive polypeptide is a hormone, (7) a method according to (6), wherein the hormone is an insulin,
(8) a method according to (6), wherein the hormone is a growth hormone, (9) a method according to (1), wherein the bioactive polypeptide is a cytokine,
(10) a method according to (9), wherein the cytokine is an interferon,
(11) a method according to (1), wherein the biodegradable polymer is an aliphatic polyester,
(12) a method according to (11), wherein the aliphatic polyester is an α-hydroxycarboxylic acid polymer,
(13) a method according to (11), wherein the aliphatic polyester is a lactic acid-glycolic acid copolymer, (14) a method according to (13), wherein the composition ratio (mol %) of lactic acid/glycolic acid of the lactic acid-glycolic acid copolymer is about 100/0 to about 40/60, and the weight-average molecular weight of the lactic acid-glycolic acid copolymer is about 3,000 to about 20,000,
(15) a method according to (1), wherein the sustained- release preparation is a particulate artifact,
(16) a method according to (15), wherein the average particle size of the particulate artifact is about 0.1 μm to about 300 μ ,
(17) a method according to (1), wherein the sustained- release preparation is for an injection,
(18) a dispersion which comprises a bioactive polypeptide dispersed in an organic solvent containing a biodegradable polymer metal salt,
(19) a sustained-release preparation as produced by the method according to (1),
(20) a sustained-release preparation according to (19), wherein the metal content of the biodegradable polymer metal salt is about 0.01 to about 10% by weight,
(21) a sustained-release preparation according to (19), wherein the concentration of the bioactive polypeptide is about 0.001 to about 30% (w/w), and (22) a sustained-release preparation according to (19), wherein the bioactive polypeptide is a growth hormone, and so on.
The biodegradable polymer of the present invention has low water soluability or is water-insoluble, and includes aliphatic polyesters, e.g., homopolymers or copolymers synthesized from one or more kinds of as- hydroxycarboxylic acids (e.g., glycolic acid, lactic acid, 2-hydroxybutyric acid, valinic acid, leucic acid, etc.), hydroxydicarboxylic acids (e.g., malic acid, etc.), hydroxytricarboxylic acids (e.g., citric acid, etc.), or their mixtures; poly-α-cyanoacrylic esters, e.g., poly(methyl α-cyanoacrylate) , poly(ethyl α- cyanoacrylate) , poly(butyl α-cyanoacrylate), etc.; and amino acid polymers, e.g., poly(γ-benzyl-L-glutamate) etc . , or their mixtures . The mode of polymerization for these biodegradable polymer may be any of random, block or graft polymerizations technique.
The preferred biodegradable polymers are aliphatic polyesters, e.g., homopolymers or copolymers synthesized from one or more kinds of α- hydroxycarbσxylic acids (e.g., glycolic acid, lactic acid, 2-hydroxybutyric acid, etc.), hydroxydicarboxylic acids (e.g., malic acid, etc.) and hydroxytricarboxylic acids (e.g., citric acid, etc.), or their mixtures, and so on.
Among the above-mentioned aliphatic polyesters, the homopolymers and copolymers synthesized from one or more kinds of the α-hydroxycarboxylic acids are preferable in view of biodegradability and biocompatibility. Particularly preferred aliphatic polyesters are copolymers synthesized from two or more kinds of the α-hydroxycarboxylic acids. Furthermore, these copolymers can be used as mixtures. When the α-hydroxycarboxylic acids are chiral compounds, they may be any of D-, L- and D-, L- configuration. It is preferable that the ratio of the D-/L-configuration (mol %) is in the range of about 75/25 to about 25/75. More preferred is a hydroxycarboxylic acid wherein the ratio of the D-/L- configuration (mol %) is in the range of about 60/40 to about 30/70.
An examples of the above mentioned α- hydroxycarboxylic acid polymer is a lactic acid polymer (hereinafter sometimes referred to as "polylactic acid") .
The α-hydroxycarboxylic acid copolymer includes copolymers of glycolic acid with the other α- hydroxycarboxylic acids such as lactic acid and 2- hydroxybutyric acid.
Preferred α-hydroxycarboxylic acid copolymers are lactic acid-glycolic acid copolymer and 2- hydroxybutyric acid-glycolic acid copolymer. A particularly preferred α-hydroxycarboxylic acid copolymer is a lactic acid-glycolic acid copolymer.
The polylactic acid may be either D-configuration or L-configuration or a mixture; one with the D-/L- configuration ratio (mol %) of about 75/25 to about 20/80 is preferred. More preferred is a polylactic acid wherein the ratio of the D-/L-configuration (mol %) is in the range of about 60/40 to about 25/75. Most preferred is a polylactic acid wherein the ratio of D- /L-configuration is in the range of about 55/45 to about 25/75.
The polylactic acid preferably has the weight average molecular weight, as defined below, of about 1,500 to about 10,000. More preferred is a polylactic acid having the weight average molecular weight of about 2,000 to about 8,000. Particularly preferred is a polylactic acid having the weight average molecular weight of about 3,000 to about 6,000. The dispersity (weight average molecular weight/number average molecular weight) of polylactic acid is preferably in the range of about 1.2 to about 4.0, and more preferably in the range of about 1.5 to about 3.5.
The polylactic acid can be produced by the prior art methods described in EP-172636 (e.g., by dehydrative polycondensation in the absence of a catalyst or by dehydrative polycondensation in the presence of an inorganic solid acid catalyst) . The preferred polylactic acid is produced by dehydrative polycondensation in the absence of a catalyst.
The compositional ratio (lactic acid/glycolic acid, mol %) in the lactic acid-glycolic acid copolymer is preferably about 100/0 to about 40/60, more preferably about 90/10 to about 45/55, and most preferably about 60/40 to about 40/60. The weight average molecular weight of the lactic acid-glycolic acid copolymer is preferably about 3,000 to about 20,000, and more preferably about 4,000 to about 15,000. The dispersity (weight average molecular weight/number average molecular weight) of the lactic acid-glycolic acid copolymer is preferably about 1.2 to about 4.0, and more preferably about 1.5 to about 3.5. The lactic acid-glycolic acid copolymers can be produced by the known methods described in EP-172636 (e.g., dehydrative polycondensation in the absence of a catalyst or dehydrative polycondensation in the presence of an inorganic solid acid catalyst) . The preferred copolymer is one produced by dehydrative polycondensation in the absence of a catalyst.
In the present invention, two kinds of lactic acid-glycolic acid copolymers differing in compositional ratio and weight average molecular weight can be used in an admixture of any ratio. The typical example is a mixture of a lactic acid-glycolic acid copolymer wherein the compositional ratio of the lactic acid/glycolic acid (mol %) is about 75/25 and the weight average molecular weight is about 6,000. Another example is lactic acid-glycolic acid copolymer wherein the compositional ratio of the lactic acid/glycolic acid (mol %) is about 50/50 and the weight average molecular weight is about 4,000. The preferred weight ratio of the mixture is about 25/75 to about 75/25. The compositional ratio of the 2-hydroxybutyric acid-glycolic acid copolymer is about 10 to about 75 mol % of glycolic acid and the remaining mol % of 2- hydroxybutyric acid, more preferably about 20 to about 75 mol % of glycolic acid, and more preferably about 30 to about 70 mol % of glycolic acid. The weight average molecular weight of 2-hydroxybutyric acid-glycolic acid copolymer is preferably about 2,000 to about 30,000, and more preferably about 3,000 to about 20,000. The particularly preferred weight average molecular weight of the copolymer is about 4,000 to about 15,000. The dispersity (weight average molecular weight/number average molecular weight) of 2-hydroxybutyric acid- glycolic acid copolymer is preferably about 1.2 to about 4.0, and more preferably about 1.5 to about 3.5. 2-Hydroxybutyric acid-glycolic acid copolymers can be produced by the known methods described in EP-172636 (e.g., dehydrative polycondensation in the absence of a catalyst or dehydrative polycondensation in the presence of an inorganic solid acid catalyst) . The preferred copolymer is one produced by dehydrative polycondensation in the absence of a catalyst.
The glycolic acid copolymers (e.g., lactic acid- glycolic acid copolymer, 2-hydroxybutyric acid-glycolic acid copolymer, etc.) may be used in an admixture with polylactic acid. When glycolic acid copolymer is used in combination with polylactic acid, the ratio of glycolic acid copolymer/polylactic acid (weight %) may be, for example, about 10/90 to about 90/10. The preferred ratio is about 20/80 to about 80/20, and the most preferred ratio is about 30/70 to about 70/30. The terms "weight average molecular weight" and "number average molecular weight" as used in this specification mean the polystyrene equivalent average molecular weight and number average molecular weight of a sample as determined by gel permeation chromatography (GPC) using 9 polystyrene standards having the weight average molecular weights of 120,000, 52,000, 22,000, 9,200, 5,050, 2,950, 1,050, 580 and 162. These determinations can be made using GPC Column KF804L x 2 (Showa Denko K. K.), RI Monitor L-3300 (Hitachi, Ltd.), and chloroform as the mobile phase.
In the present invention, biodegradable polymers synthesized by the dehydrative polycondensation reaction in the absence of a catalyst have free carboxyl groups at the terminus. Such biodegradable polymers having free carboxyl groups at the terminus feature a high correlation between the number average molecular weight determined by end-group titrimetric assay and the number average molecular weight determined by GPC assay using polystyrene standards of known molecular weights, as previously described.
By the end-group assay method, the number average molecular weight can be determined in the following manner. About 1 g to 3 g of the biodegradable polymer is dissolved in a mixed solvent of acetone (25 ml) and methanol (5 ml), and the carboxyl groups in the solution are quickly titrated with 0.05N alcoholic potassium hydroxide solution using phenoiphthalein as indicator under stirring at room temperature (about 0 to about 30°C) . The number average molecular weight is calculated by the following equation.
Number average molecular weight by end-group assay = 20000 (A/B)
A: the weight mass (g) of biodegradable polymer B: the amount (ml) of 0.05N alcoholic KOH solution added until end-point is reached In the case of a biodegradable polymer having free carboxyl groups at the terminal which is synthesized from one or more kinds of α-hydroxy acids by dehydrative polycondensation in the absence of a catalyst, a high correlation is found between the number average molecular weight determined by GPC assay and the number average molecular weight determined by the end-group assay. In contrast, in the case of a biodegradable polymer produced from the cyclic dimer of an α-hydroxy acid by the ring-opening polymerization method using a catalyst and having essentially no free carboxyl groups at the terminus, the number average molecular weight found by the end-group assay is considerably higher than the number average molecular weight found by GPC. Because of this difference, a biodegradable polymer having free carboxyl groups at the terminal can easily be differentiated from a biodegradable polymer not having free carboxyl groups at the terminus .
Whereas the number average molecular weight found by the end-group assay is an absolute value, the number average molecular weight found by GPC assay is a relative value dependent on many variables such as analytical methods and conditions (e.g., the types of mobile phase and column, reference standard, choice of slicing width, selection of baseline, etc.) and, therefore, is hard to generalize. However, a high correlation exists between the number average molecular weight found by end-group assay and the number average molecular weight found by the GPC assay when the value obtained from the end-group assay is within the range of about 0.5 to about 2.0 times the value found by the GPC assay. The preferred range is about 0.8 to about 1.5 times. That the number average molecular weight found by end-group assay is "considerably higher" than the number average molecular weight found by GPC means that the value found by the end-group assay is more than about twice the value found by the GPC assay.
In the present invention, the preferred polymers are those showing a high correlation between the number average molecular weight found by the end-group assay and the number average molecular weight found by the GPC assay.
The metal salts which can be used for converting a biodegradable polymer to its metal salt is not particularly limited as far as it does not exert bad influences in vivo. The metal salt includes a salt formed by a monovalent metal such as alkali metals (e.g., sodium, potassium, etc.) or alkaline earth metals (e.g., calcium, magnesium, etc.), or a polyvalent metal such as zinc (II), iron (II, III), copper (II), tin (II, IV), and aluminum (II, III) with an inorganic acid or an organic acid.
The metal is preferably a polyvalent metal, and more preferably alkaline earth metals and zinc.
Particularly preferred metals are calcium and zinc.
Inorganic acids that may be used in the metal salt formation include hydrogen halide (e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, hydrofluoric acid), sulfuric acid, nitric acid, thiocyanic acid, and so on.
Organic acids that may be used in the metal salt formation include aliphatic carboxylic acids and aromatic acids. Preferred aliphatic carboxylic acidε are Cj_9 aliphatic carboxylic acids, e.g., aliphatic monocarboxylic acids, aliphatic dicarboxylic acids, and aliphatic tricarboxylic acids. The aliphatic carboxylic acids may be saturated or unsaturated.
The aliphatic monocarboxylic acids include C^g saturated aliphatic monocarboxylic acids (e.g., carbonic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthoic acid, caprylic acid, pelargonic acid, capric acid, etc.) and C2-9 unsaturated aliphatic monocarboxylic acids (e.g., acrylic acid, propiolic acid, methacrylic acid, crotonic acid, isocrotonic acid, etc.).
The aliphatic dicarboxylic acids include C2_9 saturated aliphatic dicarboxylic acids (e.g., malonic acid, succinic acid, glutaric acid, adipic acid, pimellic acid, etc.) and C2_9 unsaturated aliphatic dicarboxylic acids (e.g., maleic acid, fumaric acid, citraconic acid, mesaconic acid, etc.).
The aliphatic tricarboxylic acids include C2_9 saturated aliphatic tricarboxylic acids (e.g., tri- carvallylic acid, 1,2 ,3-butanetricarboxylic acid, etc. ) .
The above mentioned aliphatic carboxylic acids additionally may have 1 or 2 hydroxyl groups. Illustrative examples are glycolic acid, lactic acid, glyceric acid, tartronic acid, malic acid, tartaric acid, citric acid, and so on.
Preferred aliphatic carboxylic acids are aliphatic monocarboxylic acids. More preferred aliphatic carboxylic acids are C2_9 aliphatic monocarboxylic acids. Particularly preferred are C2_3 saturated aliphatic monocarboxylic acids. The most preferred aliphatic carboxylic acid includes acetic acid.
Aromatic acids that may be used in the metal salt formation include benzoic acid, salicylic acid and phenolsulfonic acid. The metal salt of the biodegradable polymer, may also be obtained using the acetylacetonate or oxide of the above-mentioned polyvalent metals. Preferred metal donors of the type are zinc acetylacetonate and zinc oxide.
Metal salts which can be used for converting a biodegradable polymer to its metal salt are preferably the salt formed by a polyvalent metals with an organic or inorganic acid (hereinafter referred to as a polyvalent metal salt) .
Polyvalent metal salt that may be used include salts of zinc with an inorganic acid, e.g., zinc halides (e.g. zinc chloride, zinc bromide, zinc iodide, zinc fluoride), zinc sulfate, zinc nitrate, zinc thiocyanate, etc.; salts of zinc with an organic acid, e.g., aliphatic carboxylic acid zinc salts (e.g. zinc carbonate, zinc acetate, zinc glycolate, zinc lactate, zinc tartrate, etc.), aromatic zinc salts (e.g. zinc benzoate, zinc salicylate, zinc phenolsulfonate, etc.); salts of calcium with an inorganic acid, e.g., calcium halide (e.g., calcium chloride, calcium bromide, calcium iodide, calcium fluoride, etc.), calcium sulfate, calcium nitrate, calcium thiocyanate, etc.; salts of calcium with an organic acid, e.g., aliphatic carboxylic acid calcium salt (e.g, calcium carbonate, calcium acetate, calcium propionate, calcium oxalate, calcium tartrate, calcium lactate, calcium citrate, calcium gluconate, etc.) and aromatic calcium salts (e.g. calcium benzoate, calcium salicylate, etc.).
The preferred polyvalent metal salt includes zinc acetate and calcium acetate. The bioactive polypeptides used in the present invention include bioactive polypeptides having molecular weights from about 1,000 to about 50,000, preferably about 5,000 to about 40,000.
The representative activity of the bioactive peptide in the present invention is hormonal activity. The bioactive polypeptides may be natural products. synthetic products, semi-synthetic products, and their derivatives . The mode of action of the bioactive polypeptide may be agonistic or antagonistic.
The bioactive polypeptide for use in the present invention includes peptide hormones, cytokines, hematopoietic factors, various growth factors and enzymes .
The bioactive polypeptide hormones include insulin, growth hormone, naturiuretic peptides, gastrin, prolactin, adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), luteinizing hormone (LH) , follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG) and motilin. The preferred hormones are insulin and growth hormone. The bioactive polypeptide cytokines include lymphokines and monokines . The lymphokines includes interferons (alpha, beta and gamma) and interleukins (IL-2 to IL-12). The monokines includes interleukin-1 (IL-1), and tumor necrosis factor. The preferred cytokine is a lymphokine and, more preferred interferon. The particularly preferred cytokine is interferon-α.
The bioactive polypeptide hematopoietic factors include erythropoietin, granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), thrombopoietin, platelet-derived growth factor, and megakaryocyte potentiator.
The bioactive polypeptide growth factors include basic and acidic fibroblast growth factors (FGF) and their families (e.g., FGF-9), nerve growth factor (NGF) and itε family, inεulin-like growth factors (e.g. IGF- 1, IGF-2, etc.) and bone morphogenetic protein (BMP) and family.
The bioactive polypeptide enzymes include superoxide dismutase (SOD), tissue plasminogen activator (TPA) and kallikrein. When the bioactive polypeptide contains a metal, the metal content of the bioactive polypeptide in the present invention is preferably not greater than 0.1%, more preferably not greater than 0.01%, and most preferably not greater than 0.001%. Thus, substan¬ tially metal-free bioactive polypeptides are most suited for the present invention. Crystalline insulin, for instance, usually contains small amounts of heavy metals such as zinc, nickel, cobalt and cadmium. Insulin containing 0.4% (w/w) zinc exists as a stable hexamer and appears to be relatively inert in the interaction with the biodegradable polymer metal salt.
If necessary, the metals occurring in the bio¬ active polypeptide may be previously removed from the polypeptide by known methods. For example, one known method comprises dialyzing an aqueous hydrochlonic acid solution of insulin against water or an aqueous solution of ammonium acetate and lyophilizing the dialysate to provide amorphous insulin with minimal metal content.
In the present invention, it iε preferable that additiveε other than the biodegradable polymer metal salt in the εustained-release preparation do not form a metal salt. The biodegradable polymer metal salt in the present invention can be produced by emulsifing and dispersing an aqueous solution or solid form of a metal salt in an organic solvent solution of a biodegradable polymer to prepare a water/oil (w/o) or oil/water (o/w) emulsion or an organic solution or suspension of a biodegradable polymer containing a metal salt. The resulting substances are washed and dried or subjected to an in-water drying method, phase separation method, spray drying method or the like with washing and drying. The metal salt which does not participate in the formation of a salt with the biodegradable polymer in this process is preferably removed.
The organic solvent mentioned above preferably has a boiling point not exceeding 120°C. Such organic solvent includes halogenated hydrocarbonε (e.g., dichloromethane, chloroform, carbon tetrachloride, etc.), alcohols (e.g. ethanol, methanol, etc.), acetonitrile, and so on. These solvents can also be used as a mixture. The preferred organic solvents are dichloromethane and acetonitrile. Particularly preferred is dichloromethane.
The metal content of the biodegradable polymer metal salt is preferably about 0.01 to about 10% (w/w), more preferably about 0.05 to about 7% (w/w), and most preferably about 0.1 to about 5% (w/w). The metal content of a biodegradable polymer metal salt can be determined by atomic absorption spectrometry.
Methods for producing a biodegradable polymer metal salt (e.g., in-water drying method, phase separation method and spray drying method) are described below.
(A) In-water drying method (water/oil/water or w/o/w method)
In thiε method, the biodegradable polymer iε firεt dissolved in an organic solvent to prepare an organic εolvent εolution (hereinafter referred to sometimeε as the oil phase) . The concentration of the biodegradable polymer in this organic solvent solution is suitably selected according to the molecular weight of the polymer and the kind of organic solvent used. For example, the concentration of the biodegradabe polymer in the organic εolvent may be about 0.01 to about 90% (w/w), preferably about 0.1 to about 80% (w/w), and more preferably about 1 to about 70% (w/w) . For the internal aqueous phaεe, an aqueouε solution of metal εaltε iε used. The metal salt concentration may be from about 10 to about 90% (w/v), and preferably about 20 to about 80% (w/v) . However, the metal salt concentration depends on the solubility of the metal salt in water. The above metal salt aqueous solution is dispersed and emulsified in the organic εolvent solution of the biodegradable polymer to provide a w/o emulsion. The volume ratio of the aqueous solution of metal salts in the organic solvent solution of the biodegradable polymer iε about 1:1,000 to about 1:1, preferably about 1:100 to about 1:2, and moεt preferably about 1:50 to about 1:3. Emulsification can be achieved by conventional emulsification methods such as by using a turbine mixer, a homogenizer or the like. The w/o emulsion thus obtained is then added to an aqueous phase (the external aqueous phase) to give a w/o/w emulsion. Then the oil-phaεe εolvent iε evaporated off to provide the desired biodegradable polymer metal salt. The volume of the external aqueous phaεe may be εelected from the range of, for example, about 1 to about 10,000 times the volume of the oil phase. The preferred range is about 2 to about 5,000 times, and the most preferred range is about 5 to about 2,000 times. Solvent evaporation can be achieved by commonly used methods, including the method in which the εolvent is evaporated under normal or gradually reduced pressure while stirring using a propeller stirrer or a magnetic εtirrer, etc., and the method in which the solvent is evaporated while the degree of vacuum is adjusted using a rotary evaporator, and so on.
An emulsifier may be added to the external aqueouε phaεe. The emulεifier may be any substance capable of providing for stable w/o/w emulsionε. Examples of such emulsifiers include anionic surfactantε, nonionic surfactants, polyoxyethylene-castor oil derivativeε, polyvinylpyrrolidone, polyvinyl alcohol, carboxymethylcellulose, lecithin, gelatin, hyaluronic acid and so on. The preferred emulsifier is polyvinyl alcohol. Multiple emulsifiers may also be used in combination for use in the external aqueouε phaεe. The concentration of the emulsifier based on the external aqueous phase may be selected from the range of about 0.001 to about 20% (w/w). The preferred range is about 0.01 to about 10% (w/w) and the still more preferred range is about 0.05 to about 5% (w/w).
A metal salt which is similar to or different from the metal salt contained in the internal aqueous phase may also be added to the external aqueous phase. In such cases, preferably a fatty acid metal salt is added in such an amount that the concentration of the metal salt in the external aqueous phase is about 0.01 to 20% (w/w) or more preferably about 0.1 to 10% (w/w). By careful selection of the concentration of the metal salt in the external aqueous phase, the transfer of the metal salt used in the internal aqueous phaεe from the biodegradable polymer into the external aqueous phaεe may be avoided. The biodegradable polymer metal salt thus produced is recovered by centrifugation or filtration, washed with distilled water several times to remove the emulsifier and other deposits from the salt surface, then redispersed in distilled water, and lyophilized. (B) In-water drying method (o/w method)
In this process, a solution of the biodegradable polymer in an organic εolvent iε firεt prepared aε in method (A) .
Then, the metal εalt iε added, and dispersed or dissolved in the organic solvent solution of biodegradable polymer. The ratio of metal salt to biodegradable polymer (by weight) is about 5:1 to about 1:100, preferably about 2 : 1 to about 1:50, and more preferably about 1: 1 to about 1:10. The organic solvent solution thus obtained is then poured into an aqueous phase and an o/w emulsion iε prepared by using a turbine mixer or the like. Then, the oil-phase solvent is evaporated as in method (A) to provide the biodegradable polymer metal salt. The volume of the aqueous phase is based on the volume of oil phase and is selected from the range of, for example, about 1 to about 10,000 times the volume of the oil phase, or preferably about 2 to about 5,000 times. The most preferred range is about 5 to about 2,000 times.
As in method (A) , an emulsifier may be added into this aqueous phase.
A metal salt may be added into the aqueous phaεe that iε similar to or different from the metal salt which is added, and dispersed or dissolved in the oil phase. The biodegradable polymer metal salt thus produced is separated, washed and lyophilized as in method (A) . (C) Phase separation method (Coacervation method) For the production of a biodegradable polymer metal salt by this method, a coacervating agent is gradually added into the w/o emulsion aε used in method (A) or the organic solvent solution of biodegradable polymer containing the metal salt as used in method (B) under stirring to precipitate and solidify the biodegradable polymer metal salt. The amount of coacervating agent used is based on the volume of the w/o emulsion or organic solvent solution of the biodegradable polymer. The volume used is about 0.01 to about 1,000 timeε the volume of the W/O emulsion or organic solution of the biodegradable polymer, preferably about 0.05 to about 500 times, and more preferably about 0.1 to about 200 times.
The coacervating agent may be a substance belonging to any of the categories of polymers, mineral oils or vegetable oils, which are miεcible with the organic solvent used for dissolving the biodegradable polymer, but in which the biodegradable polymer is not appreciably soluble. Typical examples are silicone oil, sesame oil, soybean oil, corn oil, cottonseed oil, coconut oil, linseed oil, mineral oil, n-hexane, n- heptane, and so on. The coacervating agents can be used in a combination of two or more kinds . The biodegradable polymer metal salt thus produced is recovered by filtration and washed repeatedly with heptane or the like to remove the coacervating agent. The salt is then washed as in method (A) and lyophilized. In the production of a biodegradable polymer metal salt by the in-water drying method or coacervation method, an antiflocculant may be added for preventing agglomeration of the particles. Antiflocculants that may be used includ a water-soluble polysaccharides, εuch aε mannitol, lactoεe, glucoεe, and εtarches (e.g. corn starch) , hyaluronic acid and its alkali metal salt, glycine, a protein such as fibrin, collagen and an inorganic salt such as sodium chloride, sodium hydrogen phosphate, and so on. (D) Spray drying method
For the production of a biodegradable polymer metal εalt by thiε method, either a w/o emulsion prepared from an aqueous solution of the metal salt and an organic solvent solution of the biodegradable polymer, or an organic solvent solution or suspenεion of biodegradable polymer containing the metal salt, is εprayed via a nozzle into the drying chamber of a εpray drier to volatilize the organic solvent in fine dropletε in a very short time, and a fine biodegradable polymer metal salt is produced. Examples of the above¬ mentioned nozzle are a binary-fluid nozzle, a pressure nozzle and a rotary disk nozzle. An aqueous solution of the above-described antiflocculant also may be sprayed via another nozzle in order to prevent agglomeration of biodegradable polymer metal salt with the w/o emulsion or the organic solvent solution or suspension of the biodegradable polymer containing the metal salt. The biodegradable polymer metal salt thus produced is washed as in method (A) and, if necessary, further subjected to removal of water and organic solvent under heating and reduced pressure.
The sustained-release preparation of the present invention can be manufactured by dispersing a bioactive polypeptide in an organic solvent containing the bio¬ degradable polymer metal salt, and subjecting the resulting dispersion to formulation. The manufacturing method of the present invention can be used with the above-described (A) in-water drying method (w/o/w method), (B) in-water drying method (o/w method), (C) phase separation method (coacervation method), (D) spray drying method, or any modification thereof. The organic εolvent in the organic εolvent εolution iε preferably a εolvent with a boiling point not higher than 120°C. Such organic solvent includes halogenated hydrocarbons (e.g., dichloromethane, chloroform, carbon tetrachloride, etc.), alcohols (e.g., ethanol, methanol, 1,4-butanediol, 1,5-pentanediol, etc.) and acetonitrile, among otherε . Any of the εolvents can be used together as a mixture. When a single organic solvent is to be employed, dichloromethane or acetonitrile iε particularly preferred. When a mixture of organic εolventε iε to be employed, a combination of a halogenated hydrocarbon (e.g., dichloromethane) with acetonitrile or an alcohol (e.g., methanol, ethanol, etc.) is preferred. Particularly preferred in many inεtanceε iε a combination of dichloromethane with acetonitrile. The ratio (by volume) of the halogenated hydrocarbon to either acetonitrile or alcohol is about 40:1 to about 1:1 and preferably about 20:1 to about 1:1. The manufacturing method for sustained-release preparation is now described using microcapsuleε aε an example. (i) In-water drying method (w/o/w method)
In this process, an organic solvent εolution of the biodegradable polymer metal εalt iε first prepared in the same manner as in method (A) deεcribed above. The concentration of the biodegradable polymer metal salt in the organic solvent εolution iε dependent on the type and molecular weight of biodegradable polymer metal εalt and the type of the organic solvent. For example, the ratio of biodegradable polymer metal salt to organic solvent may be about 0.01 to about 80% (w/w), and is preferably about 0.1 to about 70% (w/w), and most preferably about 1 to about 60% (w/w) . For the internal aqueous phase, an aqueouε solution of the bioactive polypeptide is used. The concentration of the bioactive polypeptide in aqueous solution may be for example, about 0.1% (w/v) to about 500% (w/v), preferably about 1% (w/v) to about 400% (w/v) and more preferably about 10% (w/v) to about 300% (w/v) . To this aqueous solution may be added pH adjusting agent (e.g., acetic acid, hydrochloric acid, sodium hydroxide, etc.), stabilizers (e.g., serum albumin, gelatin, etc.), and/or preεervativeε (e.g., p- hydroxybenzoic acid eεterε, etc.). The aqueouε solution thus obtained is dispersed in the organic solvent solution of biodegradable polymer metal εalt to provide a w/o emulsion.
The ratio (v/v) of aqueous solution of bioactive polypeptide to organic solvent solution of biodegrad- able polymer metal salt is about 1:1,000 to about 1:1, preferably about 1:100 to about 1:5, and more preferably about 1:50 to about 1:5. The w/o emulsion thus obtained is then poured in an aqueous phase (external aqueous phase) to give a w/o/w emulsion and the solvent in the oil phase is evaporated to provide microcapsules. An emulsifier may be added to the external aqueous phase. The emulsifier can be any substance that is generally capable of providing a stable w/o/w emulsion. Specifically, anionic surfactants, nonionic surfactants, polyoxyethylene- castor oil derivatives, polyvinylpyrrolidone, polyvinyl alcohol, carboxymethylcellulose, lecithin, gelatin, hyaluronic acid, etc. may be employed. The preferred emulsifier is polyvinyl alcohol. Two or more kinds of emulsifiers can be used in combination. The concentration of the emulsifier based on the external aqueous phase is chosen from a range of about 0.001%
(w/w) to about 20% (w/w), preferably about 0.01% (w/w) to about 10% (w/w), and more preferably about 0.05% (w/w) to about 5% (w/w) . A metal salt, whether the same salt as that added to the internal aqueous phase or a different salt, can be added to the external aqueous phase. In this procedure, preferably a fatty acid metal salt is added so that the metal salt concentration of the external aqueous phase will be about 0.01% to about 20% (w/w) and preferably about 0.1% to about 10% (w/w). By changing the metal salt concentration of the external aqueouε phase, the metal salt used in the internal aqueous phase can be prevented from migrating from the biodegradable polymer into the external aqueous phase. The microcapεules thus produced are recovered by centrifugation or filtration, washed with diεtilled water repeatedly to remove the emulεifier and other deposits from the capsule surface, then redispersed in distilled water or the like, and lyophilized. Then, if neceεεary, residual water and organic solvent in the microcapsules are further removed by heating under reduced presεure. The microcapsuleε are heated at a temperature not below the glass transition temperature of the biodegradable polymer and not so high as to cause aggregation of the microcapsules . The heating temperature is preferably selected within the range from the glaεε transition temperature of the biodegradable polymer to about 30°C higher than the glass transition temperature of the biodegradable polymer. Here, glasε tranεition temeraiture iε defined as the intermediate glasε transition temperature determined using a differential scanning calorimeter during heating at a rate of 10 or 20°C per minute. ii^ In-water drying method (o/w methods
In this process, an organic solvent solution of the biodegradable polymer metal salt is first prepared in the same manner as in method (A) . The concentration of the biodegradable polymer metal salt in the organic solvent may be similar to that described in method (i) . In the organic solvent solution of the biodegradable polymer metal salt thus obtained iε added and dissolved or dispersed a bioactive polypeptide to prepare an organic solvent εolution or εuεpension containing the biodegradable polymer metal salt and bioactive polypeptide. The weight ratio of the bioactive polypeptide to the biodegradable polymer metal salt may for example be about 1:1000 to about 1:1, preferably about 1:200 to about 1-5 and more preferably about 1:100 to about 1:5.
This organic εolvent εolution containing the biodegradable polymer metal salt and bioactive polypeptide iε poured into an aqueouε phaεe to prepare an o/w emulsion. The solvent in the oil phase is then evaporated off to provide microcapsuleε .
The microcapsules thus obtained are recovered, washed and lyophilized as in method (i). Thereafter the microcapεules may be heated under reduced pressure to remove the residual water and organic solvent as in method (i) . (iii) Phase separation method In the production of microcapsules by this method, a coacervating agent iε gradually added to the εame w/o emulεion aε used in method (i) or the same organic solvent solution of biodegradable polymer metal salt and bioactive polypeptide as used in method (ii) under stirring in the same manner aε in method (C) to afford precipitated and solidified microcapsules.
The microcapsules thus produced are recovered and washed to remove the coacervating agent and free bioactive polypeptide as in method (C) . Then, if necessary, the residual water and organic solvent within the microcapsuleε are removed by heating under reduced pressure in the same manner as in method (i).
In the production of microcapsules by the in-water drying method or phase separation method, an antiflocculant may be added for preventing agglomeration of particles as in method (C) . (iv) Spray-drying method
In the production of microcapsules by this method, the same w/o emulsion as used in method (i) or the same organic solvent solution containing the biodegradable polymer metal salt and bioactive polypeptide aε uεed in method (ii) is sprayed via a nozzle in the same manner as in method (D) to provide microcapsules.
If necessary, the microcapsules thus obtained are heated under reduced presεure to remove residual water and organic solvent as in method (i).
In the present invention, it is preferable that the efficiency of entrapment of a bioactive polypeptide into a biodegradable polymer iε over 50%.
The concentration of bioactive polypeptide comprised in the sustained-release preparation in the present invention is, for example, about 0.001 to about 30% (w/w), preferably about 0.02 to about 20% (w/w), more preferably about 0.1 to about 10% (w/w), and most preferably about 0.5 to about 5% (w/w). The sustained-release preparation may be administered in the form of microcapεule or in variouε dosage forms such as non-oral preparations (e.g., intramuscular-, subcutaneouε- or viεceral- injectable or indwellable preparation; nasal-, rectal or uterine- tranεmucoεal preparation), or oral preparationε (e.g., capεuleε εuch aε hard capsule and soft capsule, solid preparations such as in granules and powder, liquid preparations such as a suspension) .
The particularly preferred sustained-release preparation is by injection. To prepare an injection using the microcapsules obtained above, the microcapsuleε may be formulated with a dispersant (e.g., surfactantε εuch aε Tween 80, HCO-60; polyεaccharideε such as carboxymethylcellulose, sodium alginate, sodium hyaluronate; protamine εulfate; polyethylene glycol 400, etc.), a preεervative (e.g., methyl paraben, propyl paraben, etc.), an iεotonizing agent (e.g., εodium chloride, mannitol, εorbitol, glucoεe, etc.), and a local anesthetic (e.g., xylocaine hydrochloride, chlorobutanol, etc.) to provide an aqueous suspenεion, or diεperεed with vegetable oil (e.g., εesame oil, corn oil, etc.), or a mixture thereof with a phospholipid (e.g., lecithin) or medium- chain fatty acid triglycerides (e.g., Migriol 812) to provide an oily suspension. When the sustained-releaεe preparation iε micro¬ capsules, the microcapsules are preferably fine particle. The size of microcapεuleε for an injectable εuεpension may be selected from the range satisfying the requirements for the degree of dispersion and passage through the needle used for the injection. For example, the microcapsul perticle size may be within the range of about 0.1 to about 300 μm, preferably about 1 to about 150 μm and more preferably about 2 to about 100 μm. Methods of preparing microcapsules as a sterile preparation include, but are not limited to, the method in which the entire production process is sterile, the method in which gamma rays are used as the sterilant, and method in which an antiseptic is added during the manufacturing process. The suεtained-releaεe preparation can be safely used in mammals (e.g., humans, bovine, swine, dogs, cats, mice, rats, rabbits, etc.) with low toxicity.
The εpecific application of the sustained-releaεe preparation varieε from kinds of the bioactive polypeptides .
For example, εustained-release preparation is useful to prevent or treat diabetes when insulin is used as bioactive the polypeptide; growth hormone hyposecretion and Turner's syndrome when growth hormone is used; viral hepatitiε (e.g., type C hepatitiε, HBe antigen-poεitive active heptitiε) and cancer (e.g., renal carcinoma, multiple myeloma, etc.) when interferon-α iε uεed; anemia (e.g., anemia during a dialysis of kidney) when erythropoietin is used; neutropenia (e.g., in therapy of carcinostotic) and infections when G-CSF is used; cancer (e.g., hemangioendothelioma) when IL-2 iε uεed; gaεtrointestinal ulcer when FGF-9 is used; senile dementia and neuropathy when NGF is used; thrombosis when TPA is uεed; and cancer when tumor recrosis factor is used.
Dosage of the suεtained-release preparation is the effective concentration of the bioactive polypeptide in vivo, though the dosage varies with the type of the bioactive polypeptide, the desired duration of the release, the target diεease, the subject animal species and the other factors .
When the sustained-release preparation is a one- week-long action formulation, the dosage of the bioactive polypeptide can be choεen from the range of about 0.0001 to about 10 mg/kg body weight per an adult. The more preferred dosage can be suitably chosen from the range of about 0.0005 to about 1 mg/kg body weight. The preferred administration frequency of the sustained-release preparation may be suitably chosen from once a week to once every two weeks depending on the type of bioactive polypeptide, the dosage form, the duration of the release, the target diseaεe, the subject animal species and other factors. For example, when insulin is the bioactive polypeptide contained in the sustained-release preparation, the dosage for an adult diabetic can be usually selected from the range of about 0.001 to about 1 mg (as active ingredient) /kg body weight and preferably from the range of about 0.01 to about 0.2 mg/kg body weight with the doεage form to be adminiεtered on a weekly basis. In the case of growth hormone, the doεage for a patient with pituitary dwarfiεm is chosen from the range of about 0.004 mg to about 4 mg/kg body weight and preferably about 0.04 mg to about 0.8 mg/kg body weight aε the active ingredient and iε preferably adminiεtered at one-week intervals. Alternatively, the dosage can be chosen from a range of about 0.008 mg to about 8 mg/kg body weight and preferably about 0.08 mg to about 1.6 mg/kg body weight, for administration every 2 weeks.
The εuεtained-releaεe preparation iε preferably εtored at room temperature or in the cold. More preferably, the sustained-releaεe preparation is εtored in the cold. "Room temperature" meanε 15° to 25°C, and "cold" meanε a temperature below 15°C.
Beεt Mode for Carrying Out the Invention
The following reference exampleε and working ex¬ ampleε are intended to describe the present invention in further detail and should not be construed as limiting the εcope of the invention. Reference example 1
4 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (mol %), weight average molecular weight 6000) was dissolved in 4 ml of dichloromethane. To this solution was added 1 ml of
438 mg/ml aqueous zinc acetate solution and the mixture was agitated in a bench-top homogenizer to prepare a w/o emulsion. This emulsion was poured into 800 ml of a 0.1% (w/v) aqueous polyvinyl alcohol (PVA) solution, the temperature of which was preadjusted to 18°C, and using a turbine homo-mixer, a w/o/w emulsion was prepared. Then, with this w/o/w emulsion being agitated at room temperature, the dichloromethane was evaporated off to produce a lactic acid-glycolic acid copolymer zinc salt. This lactic acid-glycolic acid copolymer zinc salt was recovered by centrifugation (about 1000 rpm) and the supernatant was discarded. The pellet was waεhed with 600 ml of diεtilled water twice and lyophilized to provide a powder of lactic acid-glycolic acid copolyme zinc salt. The zinc content of thiε εalt as meaεured by atomic abεorption εpectrometry waε 1.36% (w/w).
Reference Example 2 4 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (ml %), weight average molecular weight 10000) was dissolved in 4 ml of dichloromethane. To thiε solution waε added 1.5 ml of 292 mg/ml aqueouε zinc acetate solution and the mixture was agitated in a bench-top homogenizer to prepare a w/o emulsion. This emulεion was treated in the same manner as in Reference Example 1 to provide a powder of lactic acid-glycolic acid copolymer zinc salt. The zinc content of this salt as measured by atomic absorption spectrometry was 1.1% (w/w). Reference Example 3
4 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (mol %), weight average molecular weight 15000) was dissolved in 4 ml of dichloromethane. To this solution was added 1.5 ml of 292 mg/ml aqueous zinc acetate solution and the mixture waε agitated in a bench-top homogenizer to prepare a w/o emulεion. Thiε emulεion was treated as in Reference Example 1 to provide a powder of lactic acid- glycolic acid copolymer zinc salt. The zinc content of this εalt aε measured by atomic absorption spectrometry was 0.99%.
Reference Example 4 1 g of recombinant human insulin (Wako Pure
Chemical Industrieε, zinc content 0.35%) waε diεεolved in 200 ml of 0. OIN-hydrogen chloride solution. Then, using a semipermeable membrane with a molecular weight
TM of 6000 cut-off (Spectrapor 7 MWCO 1000, Spectrum Medical Industries, U.S.A.), the above solution was dialyzed againεt 10 L of 0.01N hydrogen chloride solution 3 times. The dialysate was further dialized against 30 L of 0.2M aqueous ammonium acetate solution once, 30 L of distilled water once and, then, lyophilized. The zinc content of the lyophilized insulin powder was lesε than 0.0001% (w/w).
Reference Example 5
8 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (mol %), weight average molecular weight 6000) waε diεεolved in 8 ml of dichloromethane. To this solution was added 1.5 ml of 292 mg/ml aqueous zinc acetate solution and using a bench-top homogenizer, a w/o emulsion was prepared. This emulsion was added to 1800 ml of 0.1% (w/v) aqueous polyvinyl alcohol solution which had been preadjusted to 18°C, and uεing a turbine homogenizer, a w/o/w emulεion was prepared. This emulsion was treated as in Reference Example 1 to provide a powdery lactic acid-glycolic acid copolymer zinc salt. As determined by atomic absorption spectrometry, the zinc content of this lactic acid-glycolic acid copolymer zinc salt was 1.15%.
Reference Example 6 8 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (mol %), weight average molecular weight 6000) was dissolved in 8 ml of dichloromethane. To this solution was added 1.5 ml of 292 mg/ml aqueous zinc acetate solution, and using a bench-top homogenizer, a w/o emulsion was prepared.
This emulεion was treated as in Reference Example 4 to provide a powdery lactic acid-glycolic acid copolymer zinc εalt. As determined by atomic absorption εpectro etry, the zinc content of this lactic acid-gly- colic acid copolymer zinc salt was 1.24%.
Reference Example 7
8 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (mol %), weight average molecular weight 15000) was dissolved in 8 ml of dichloromethane. To this solution was added 1.2 ml of 292 mg/ml aqueous zinc acetate solution, and using a bench-top homogenizer, a w/o emulsion was prepared. This emulsion was treated as in Reference Example 4 to provide a powdery lactic acid-glycolic acid copolymer zinc salt. Aε determined by atomic abεorption spectrometry, the zinc content of thiε lactic acid-gly¬ colic acid copolymer zinc salt was 0.96%.
Reference Example 8
8 g of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (mol %), weight average molecular weight 8000) waε diεεolved in 8 ml of dichloromethane. To this solution was added 1.5 ml of 292 mg/ml aqueous zinc acetate solution, and using a bench-top homogenizer, a w/o emulsion was prepared. This emulsion was added to 1800 ml of 0.1% (w/v) aqueous polyvinyl alcohol solution which had been preadjusted to 18°C, and uεing a turbine homogenizer, a w/o/w emulsion was prepared. Then, while stirring the w/o/w emulεion at room temperature, the dichloromethane εolvent waε evaporated off to give a lactic acid- glycolic acid copolymer zinc salt. This lactic acid— glycolic acid copolymer zinc εalt was harvested by centrifugation (about 1000 rpm) and the εupernatant waε discarded. The salt waε rinεed with 1200 ml of diεtilled water twice. This procedure was repeated a second time and the second crop waε combined with the first crop, and the mixture was lyophilized to provide 11.8 g of lactic acid-glycolic acid copolymer zinc salt in a powdery form. As determined by atomic abεorption spectrometry, the zinc content of this lactic acid- glycolic acid copolymer zinc salt was 1.19 % (w/w).
Example 1 900 mg of the lactic acid-glycolic acid copolymer zinc εalt obtained in Reference Example 1 was disεolved in 1 ml of dichloromethane. To thiε εolution waε added 100 mg of the lyophilized Zn-free inεulin powder prepared in Reference Example 4 and the mixture waε agitated in a bench-top homo-mixer to prepare an organic εolvent εolution containing both the inεulin and the lactic acid-glycolic acid copolymer zinc salt. This organic solvent solution waε poured in 800 ml of 0.1% (w/v) aqueous polyvinyl alcohol (PVA) solution preadjusted to 18°C and using a turbine homogenizer, an o/w emulsion was prepared. Then, while the o/w emulsion was agitated at room temperature, the dichloromethane was evaporated off to provide microcapsules . The microcapsules were recovered by centrifugation (about 1000 rpm) and the supernatant was discarded. The pellet waε rinsed with 600 ml of distilled water twice and lyophilized to provide 520 mg of powdery insulin-containing microcapsules .
Example 2 900 mg of the lactic acid-glycolic acid copolymer zinc salt prepared in Reference Example 2 was dissolved in 1 ml of dichloromethane. To this solution was added 100 mg of the lyophilized Zn-free insulin powder obtained in Reference Example 4 and the mixture was treated as in Example 1 to provide 450 mg of powdery insulin-containing microcapsuleε .
Example 3
900 mg of the lactic acid-glycolic acid copolymer zinc salt prepared in Reference Example 3 was diεεolved in 1.5 ml of dichloromethane. To thiε solution was added 100 mg of the lyophilized Zn-free inεulin powder obtained in Reference Example 4 and the mixture was treated as in Example 1 to provide 503 mg of powdery insulin-containing microcapsules.
Example 4
950 mg of the lactic acid-glycolic acid copolymer zinc salt prepared in Reference Example 1 was dissolved in 1.5 ml of dichloromethane. To this solution was added the powder from 8 vials (128 IU) of human growth hormone (Genotropin 16IU/ampule, Sumitomo pharmaceutical Company Limited) and the mixture was treated as in Example 1 to provide 500 mg of growth hormone-containing microcapsules . Example 5
950 mg of the lactic acid-glycolic acid copolymer zinc salt obtained in Reference Example 5 was dissolved in 1.5 ml of dichloromethane. To this solution was added 50 mg of lyophilized human growth hormone powder and the mixture was treated as in Example 1 to provide 517 mg of powdery growth hormone-containing microcapsules .
Example 6
950 mg of the lactic acid-glycolic acid copolymer zinc salt obtained in Reference Example 3 was dissolved in 3 ml of dichloromethane. To this solution waε added 50 mg of lyophilized human growth hormone powder and the mixture waε treated aε in Example 1 to provide 415 mg of powdery growth hormone-containing microcapsules .
Example 7 475 mg of the lactic acid-glycolic acid copolymer zinc salt obtained in Reference Example 6 and 475 mg of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (mol %), weight average molecular weight 6000) were diεεolved in 1.5 ml of a mixture of dichloromethane and ethanol (di- chloromethane/ethanol = 2/1 (v/v) ) . To this solution waε added 50 mg of lyophilized human growth hormone powder and the mixture waε treated as in Example 1 to provide 249 mg of powdery growth hormone-containing microcapsules.
Example 8
475 mg of the lactic acid-glycolic acid copolymer zinc salt obtained in Reference Example 7 and 475 mg of lactic acid-glycolic acid copolymer (lactic acid/glycolic acid = 50/50 (mol %), weight average molecular weight 15000) were dissolved in 3 ml of dichloromethane-ethanol (2/1, v/v) . To this solution was added 50 nig of lyophilized human growth hormone powder and the mixture was treated as in Example 1 to provide 447 mg of powdery growth hormone-containing microcapsules .
Example 9
2.12 g of the lactic acid-glycolic acid copolymer zinc salt obtained in Reference Example 8 was dissolved in 3.45 ml of dichloromethane. Then, 160 mg of the lyophilized zinc-free insulin powder obtained in Reference Example 4 was added to 2 ml of dichloromethane and sonicated for 5 minutes to prepare an insulin suspension. To this suspension was added the above dichloromethane solution of lactic acid- glycolic acid copolymer zinc salt (corresponding to 1.84 g of lactic acid-glycolic acid copolymer zinc salt) . The mixture was treated with a vortex mixer and, then, with a bench-top homogenizer to give an organic solvent solution containing both insulin and lactic acid-glycolic acid copolymer zinc salt. This organic solvent solution was added to 2000 ml of a 0.1% (w/v) aqueous polyvinyl alcohol solution containing 1.4% of zinc acetate dihydrate preadjusted to 18°C, and using a turbine homomixer, an o/w emulsion was prepared. Then, while the o/w emulsion was agitated at room temperature, the dichloromethane was evaporated off to provide microcapsules. The microcapsules were harvested by centrifugation (about 1000 rpm) and the supernatant was discarded. The microcapsules were rinsed with 1200 ml of distilled water twice, and after addition of 250 mg of mannitol, they were lyophilized to provide 1.53 g of powdery insulin-containing microcapsules. Example 10
1.06 g of the lactic acid-glycolic acid copolymer zinc salt obtained in Reference Example 8 was disεolved in 2.3 ml of dichloromethane/acetonitrile (10/1, v/v). Meanwhile, 80 mg of the lyophilized zinc-free insulin powder obtained in Reference Example 4 was added to 1 ml of dichloromethane/acetonitrile (10/1, v/v) and εonicated for 5 minuteε to prepared an insulin suspension. To this suεpenεion waε added the above dichloromethane solution of lactic acid-glycolic acid copolymer zinc salt (corresponding to 0.92 g of lactic acid-glycolic acid copolymer zinc salt) and the mixture was processed with a vortex mixer and further with a bench-top homogenizer to prepare an organic solvent solution containing both insulin and the lactic acid- glycolic acid copolymer zinc salt. This organic εolvent solution was added to 1000 ml of a 0.1% (w/v) aqueous polyvinyl alcohol solution containing 0.7% (w/v) of zinc acetate dihydrate, which had been preadjusted to 18°C, and using a turbine homogenizer, an o/w emulsion was prepared. While the o/w emulsion was agitated at room temperature, the dichloromethane waε evaporated off to provide microcapεuleε . The microcapsules were harvested by centrifugation (about 1000 rpm) and the supernatant waε diεcarded. The microcapεuleε were washed with 600 ml of diεtilled water twice, followed by addition of 100 mg of mannitol and lyophilization to provide 0.734 g of powdery insulin-containing microcapsules .
Experimental Example 1
147 mg of the insulin-containing microcapsules prepared in Example 1 was dispersed in 1.75 ml of dispersion medium (mannitol 5% (w/v), carboxymethylcellulose 0.5% (w/v), Tween 20 0.1% (w/v), adjusted to pH 6.8 with acetic acid). A 0.5 ml portion (insulin content 100 U) of this dispersion was injected subcultaneously at the back of streptozocin-induced hyperglycemic rats under ether anesthesia. Blood was serially drawn from the tail vein and the serum was separated. The concentration of insulin in each serum sample was determined by enzyme immunoassay using the two-antibody sandwich method. As controls, insulin solution and Novolin U (Novo-Nordisk, Denmark), a commercial insulin delayed action preparation, (both containing 100 U insulin equivalent) were administered. The results are shown in Table 1. Thus, the serum insulin concentration in the insulin zinc-containing microcapsule treatment group was significantly well- sustained as compared with insulin solution and Novolin U, indicating that the sustained dosage form prepared by the method of the present invention has improved sustained-release characteristicε .
Table 1 Time courses of blood insulin concentration after administration of various insulin preparations
Insulin Blood concentration (μU/ml) prepa¬ ration 0.5 1 hr. 2 hr. 4 hr. 8 hr. 24 48 72 hr. hr. hr. hr.
Insulin 33,600 50,000 47,500 700 130 <10 <10 <10 solution
Novolin U 14 569 1,830 39,500 3,600 18 <10 <10
Micro¬ 55 485 1,370 11,400 4,630 3,630 601 47 capsule
Experimental Example 2
261 mg of the growth hormone-containing microcapsules obtained in Example 6 was dissolved in
1.75 ml of disperεion medium. A 0.5 ml portion of the dispersion (corresponding to 3 mg of growth hormone) was administered subcutaneously at the back of rats under ether anesthesia. As a control, a solution of growth hormone (containing 3 mg of growth hormone) was similarly administered. Blood was drawn serially from the tail vein and the serum was separated. The concentration of growth hormone in each serum sample was determined by radioimmunoassay (Ab Bead HGH, Eiken Kagaku) . The results are presented in Table 2. Thus, the serum growth hormone concentration was sustained significantly longer in the growth hormone/zinc- containing microcapsule group, compared with the growth hormone solution group, suggesting an outstanding prolonged action characteristic of the sustained release dosage form manufactured by the method of the present invention.
Experimental Example 3
211 mg of the growth hormone-containing microcapsules obtained in Example 7 was dissolved in 1.75 ml of disperεion medium. A 0.5 ml portion of this dispersion (containing 3 mg of growth hormone) was adminiεtered subcutaneously at the back of ether- anesthetized ratε . Blood was drawn serially from the tail vein and the serum εeparated. The concentration of growth hormone in each serum εample was determined by radioimmunoassay (Ab Bead HGH, Eiken Kagaku) . The results are presented in Table 2. Thus, the serum growth hormone concentration in the growth hormone/zinc-containing microcapsule group waε sustained significantly longer compared with the growth hormone solution group, with a marked suppresεion of initial releaεe bursts, therefore suggesting an outstanding prolonged action characteristic of the sustained release dosage form manufactured by the method of the present invention. Table 2
Time courses of blood growth hormone concentration after administration of variouε growth hormone preparations
Growth Blood concentration (ng/ml) hormone prepa¬ 1 hr. 2 hr. 8 hr. 1 2 3 4 5 7 ration day day day day day day
Growth 7,796 3,462 45 1 N.D. N.D. N.D. N.D. N.D. hormone solution
Micro¬ 688 1,234 265 8 25 13 16 17 14 capsule of Example 2
Micro¬ 12 55 8 4 2 4 3 6 capsule of Example 3
Experimental Example 4 236.6 mg of the insulin-containing microcapsules obtained in Example 9 was dissolved in 1.75 ml of dispersion medium. A 0.5 ml portion (containing 100 U of insulin) of this dispersion was administered subcutaneously at the back of ether-anesthetized rats. Blood waε drawn serially from the tail vein and the serum separated. Insulin concentration in each serum sample was determined by enzyme-linked immunosorbent assay. The results are presented in Table 3. Thus, the serum insulin concentration in the insulin/zinc- containing microcapsule group was suεtained significantly longer compared with the insulin solution group, with marked inhibition of initial release bursts, suggesting an outstanding prolonged action characteristic of the sustained release dosage form manufactured by the method of the present invention. Experimental Example 5
216.4 mg of the insulin-containing microcapsules obtained in Example 10 was disεolved in 1.75 ml of dispersion medium. A 0.5 ml portion (containing 100 U of insulin) of the above disperεion was administered subcutaneously at the back of ether-anesthetized rats. Blood was drawn serially from the tail vein and the serum separated. The concentration of insulin in each serum sample was determined by enzyme-linked immunosorbent aεεay. The results are presented in Table 3. Thus, the serum insulin concentration in the insulin/zinc-containing microcapsule group was sus¬ tained significantly longer compared with the insulin solution group, with marked inhibition of initial release bursts, suggesting an outstanding prolonged action characteristic of the sustained release dosage form manufactured by the method of the invention.
Table 3
Time courses of blood insulin concentration after administration of variouε insulin preparations
Insulin Blood concentration (μU/ml) preparation
1 hr. 2 hr. 8 hr. 1 2 3 4 5 6 7 day day day day day day day
Insulin 50,000 47,500 130 N.D. N.D. N.D. N.D. N.D. N.D. N.D. solution
Microcapsule 26 661 3,387 218 158 172 427 420 149 152 of Example 4
Microcapsule 158 744 1,916 783 642 655 1,185 982 251 86 of Example 5
Industrial Applicability
In accordance with the present invention, there can be provided a sustained-release preparation with an enhanced rate of entrapment of bioactive polypeptides, inhibited early burstε of release after administration, and constant release kinetics over a long time.

Claims

1. A method of producing a sustained-release preparation which comprises dispersing a bioactive polypeptide in an organic solvent containing a biodegradable polymer metal salt, and subjecting the resulting dispersion to formation.
2. A method according to Claim 1, wherein the metal salt iε a polyvalent metal εalt.
3. A method according to Claim 1, wherein the metal salt is selected from the group consisting of a zinc salt and a calcium salt.
4. A method according to Claim 1, wherein the organic solvent is a mixture of halogenated hydrocarbons and acetonitrile or alcohols .
5. A method according to Claim 4, wherein the organic solvent mixture ratio of halogenated hydrocarbons to acetonitrile or alcohols is in the range of about 40:1 to about 1:1 (volume/volume).
6. A method according to Claim 1, wherein the bioactive polypeptide is a hormone.
7. A method according to Claim 6, wherein the hormone is an insulin.
8. A method according to Claim 6, wherein the hormone is a growth hormone.
9. A method according to Claim 1, wherein the bioactive polypeptide is a cytokine.
10. A method according to Claim 9, wherein the cytokine is an interferon.
11. A method according to Claim 1, wherein the biodegradable polymer is an aliphatic polyester.
12. A method according to Claim 11, wherein the aliphatic polyester is an α-hydroxycarboxylic acid polymer.
13. A method according to Claim 11, wherein the aliphatic polyester is a lactic acid-glycolic acid copolymer.
14. A method according to Claim 13, wherein the compoεition ratio (mol %) of lactic acid/glycolic acid of the lactic acid-glycolic acid copolymer iε about 100/0 to about 40/60, and the weight-average molecular weight of the lactic acid-glycolic acid copolymer iε about 3,000 to about 20,000.
15. A method according to Claim 1, wherein the εustained-release preparation is a particulate artifact.
16. A method according to Claim 15, wherein the average particle size of the particulate artifact is about 0.1 μm to about 300 μm.
17. A method according to Claim 1, wherein the sustained-release preparation is for an injection.
18. A disperεion which compriεeε a bioactive polypeptide diεperεed in an organic εolvent containing a biodegradable polymer metal εalt.
19. A εuεtained-releaεe preparation aε produced by the method according to Claim 1.
20. A sustained-release preparation according to Claim 19, wherein the metal content of the biodegradable polymer metal salt is about 0.01 to about 10% by weight.
21. A suεtained-releaεe preparation according to Claim 19, wherein the concentration of the bioactive polypeptide is about 0.001 to about 30% (w/w) .
22. A sustained-release preparation according to Claim 19, wherein the bioactive polypeptide is a growth hormone.
PCT/JP1996/001770 1995-06-27 1996-06-26 Method of producing sustained-release preparation Ceased WO1997001331A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU62420/96A AU6242096A (en) 1995-06-27 1996-06-26 Method of producing sustained-release preparation
AT96921094T ATE268591T1 (en) 1995-06-27 1996-06-26 METHOD FOR PRODUCING DELAYED RELEASE PREPARATIONS
EP96921094A EP0835101B1 (en) 1995-06-27 1996-06-26 Method of producing sustained-release preparation
DE69632684T DE69632684T2 (en) 1995-06-27 1996-06-26 PROCESS FOR PREPARING PREPARED DELETION PREPARATIONS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16120495 1995-06-27
JP7/161204 1995-06-27
JP10240396 1996-04-24
JP8/102403 1996-04-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/571,728 Continuation US6267981B1 (en) 1995-06-27 2000-05-15 Method of producing sustained-release preparation

Publications (2)

Publication Number Publication Date
WO1997001331A2 true WO1997001331A2 (en) 1997-01-16
WO1997001331A3 WO1997001331A3 (en) 1997-02-27

Family

ID=26443118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/001770 Ceased WO1997001331A2 (en) 1995-06-27 1996-06-26 Method of producing sustained-release preparation

Country Status (9)

Country Link
US (1) US6267981B1 (en)
EP (1) EP0835101B1 (en)
JP (1) JP2008273982A (en)
AR (1) AR005275A1 (en)
AT (1) ATE268591T1 (en)
AU (1) AU6242096A (en)
CA (1) CA2224381A1 (en)
DE (1) DE69632684T2 (en)
WO (1) WO1997001331A2 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048519A1 (en) * 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
EP0905143A3 (en) * 1997-09-26 2000-09-06 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc and use
US6204247B1 (en) 1997-08-15 2001-03-20 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
WO2001030320A1 (en) * 1999-10-22 2001-05-03 Amgen Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2002043709A1 (en) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Method for producing preparation containing bioactive substance
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6589547B1 (en) * 1998-03-04 2003-07-08 Takeda Chemical Industries, Ltd. Sustained-release preparation for AII antagonist, production and use thereof
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP1258254A4 (en) * 2000-02-21 2004-02-04 Takeda Chemical Industries Ltd SLOW-RELEASE PREPARATIONS CONTAINING A PHYSIOLOGICALLY ACTIVE COMPOUND, NOT SO SOLUBLE IN WATER, AND METHOD OF PRODUCING AND USING THE SAME
US6723347B1 (en) 1999-09-17 2004-04-20 Takeda Chemical Industries, Ltd. Proces for producing protein powder
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
US7452860B2 (en) 2001-03-23 2008-11-18 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US7476652B2 (en) 2002-06-18 2009-01-13 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US9376479B2 (en) 2002-12-31 2016-06-28 Anjinomoto Althea, Inc. Human growth hormone crystals and methods for preparing them
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US11535659B2 (en) 2010-09-28 2022-12-27 Amryt Pharmaceuticals Inc. Engineered polypeptides having enhanced duration of action
US12558307B2 (en) 2009-07-06 2026-02-24 Sanofi-Aventis Insulin preparations containing methionine

Families Citing this family (305)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US7708915B2 (en) * 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
EP1382350A4 (en) * 2001-04-25 2006-01-04 Takeda Pharmaceutical REMEDIES AGAINST POSTOPERATIVE RECURRENCE OF BREAST CANCER IN WOMEN IN PREMENOPAUSE
US7320756B2 (en) * 2001-05-05 2008-01-22 Debasish Mukhopadhyay Method and apparatus for treatment of feedwaters by membrane separation under acidic conditions
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
WO2003024430A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
AU2002346960A1 (en) 2001-10-06 2003-04-22 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
CA2464889A1 (en) * 2001-11-02 2003-05-08 Sekisui Chemical Co., Ltd. Cytokine-inducing material and cytokine-inducing instrument
EP1572933A4 (en) 2002-02-13 2007-09-05 Univ Duke MODULATION OF IMMUNE RESPONSE BY POLYPEPTIDES OF RESPONSE TO STRESS BINDING TO NON PEPTIDES
RU2005102604A (en) * 2002-07-03 2005-09-10 Перикор Сайенс, Инк. (Us) COMPOSITION OF HYALURONIC ACID AND METHODS OF APPLICATION
EP2301573A1 (en) 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
SI1551876T1 (en) 2002-10-16 2011-07-29 Purdue Pharma Lp Antibodies that bind cell-associated ca 125/0722p and methods of use thereof
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
US20090275730A1 (en) * 2004-10-20 2009-11-05 Hiroyuki Oku Temperature responsive depsipeptide polymer
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
WO2007076131A2 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
JP5738516B2 (en) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド Sustained release of neuregulin to improve cardiac function
WO2007106537A2 (en) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
AU2007225139A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
CA2644784A1 (en) * 2006-03-13 2007-09-20 Jinling Chen Formulations of sitaxsentan sodium
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
CN101535304A (en) 2006-09-21 2009-09-16 埃迪威克斯生物科学公司 Serine hydrolase inhibitors
BRPI0715579A2 (en) 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "compound, pharmaceutical composition and use of a compound"
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
BRPI0808089A2 (en) * 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc METHOD TO TREAT LIVER DISEASE, TO REDUCE A HIGH LEVEL OF A LIVER ENZYME, TO INHIBIT A TNF-ALPHA SIGNALING RULE, TO REDUCE A LIVER DAMAGE TO APPLY EXCESSIVE IN A LIVER CELL, AND TO INHIBIT HEPATITE C VIRUS REPLICATION.
ES2693948T3 (en) 2007-03-15 2018-12-14 Auspex Pharmaceuticals, Inc. Substituted phenethylamine with serotonergic and / or norepinephrinergic activity
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
MX2010000465A (en) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND ALTERATIONS RELATED TO TUMORS.
CN101855228B (en) * 2007-09-11 2012-10-24 杏林制药株式会社 Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PL2947072T3 (en) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
AU2009249600A1 (en) * 2008-05-20 2009-11-26 Cerenis Therapeutics Holding S.A. Niacin and NSAID for combination therapy
WO2010014134A1 (en) 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
PL2401267T3 (en) * 2009-02-27 2014-06-30 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and their use in methods
JP5690286B2 (en) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド Phosphothiophene and phosphothiazole HCV polymerase inhibitors
JP2012520314A (en) 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン Combination of indazolylaminopyrrolotriazine and taxane for cancer treatment
KR101748891B1 (en) * 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 7-cycloalkylaminoquinolones as gsk-3 inhibitors
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
AR076363A1 (en) 2009-04-22 2011-06-08 Axikin Pharmaceuticals Inc ARILSULFONAMIDE CCR3 ANTAGONISTS
SG175748A1 (en) 2009-04-22 2011-12-29 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
PE20120810A1 (en) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc COMPOUNDS DERIVED FROM 5-CYANE-2- (PHENYLTHIUM) BENCENSULFONAMIDE AS ANTAGONISTS OF CCR3
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
ES2655883T5 (en) 2009-07-08 2022-04-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Pharmaceutical compositions containing sodium thiosulfate
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
BR112012003661A2 (en) 2009-08-19 2017-04-25 Ambit Biosciences Corp "Biaryl compounds and methods of use thereof."
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2515654A4 (en) * 2009-12-23 2013-04-24 Map Pharmaceuticals Inc Novel ergoline analogs
AU2010339460A1 (en) 2009-12-30 2012-07-19 Scynexis Inc. Cyclosporine analogues
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP2531197B1 (en) 2010-02-05 2017-05-17 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
SG10201501062SA (en) 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP2542542B1 (en) 2010-03-02 2015-04-22 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
WO2011116161A2 (en) 2010-03-17 2011-09-22 Axikin Pharmaceuticals Inc. Arylsulfonamide ccr3 antagonists
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
CA2801003A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
WO2011153197A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
NZ604018A (en) 2010-06-07 2015-02-27 Novomedix Llc Furanyl compounds and the use thereof
MX347927B (en) 2010-07-19 2017-05-19 Summa Health System VITAMIN C AND VITAMIN K FREE OF CHROME, AND COMPOSITIONS OF THESE TO TREAT A STATE OR DISEASE IN WHICH NFKB INTERvenes.
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
US8912324B2 (en) 2010-09-01 2014-12-16 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611792B1 (en) 2010-09-01 2017-02-01 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
AU2011296024B2 (en) 2010-09-01 2015-05-28 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
EP2611502A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20120088769A1 (en) 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
JP2013545749A (en) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP2014503597A (en) 2011-01-31 2014-02-13 セルジーン コーポレイション Pharmaceutical composition of cytidine analogue and method of use thereof
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
EP2683383B1 (en) 2011-03-11 2017-11-29 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CN103842369A (en) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2723735A4 (en) 2011-06-23 2015-02-18 Map Pharmaceuticals Inc Novel fluoroergoline analogs
JP6027610B2 (en) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL2750699T3 (en) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR088441A1 (en) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
MY167575A (en) 2011-10-14 2018-09-20 Ambit Biosciences Corp Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
TW201331221A (en) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
AU2012355982A1 (en) 2011-12-19 2014-07-10 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
TW201341367A (en) 2012-03-16 2013-10-16 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
CN114939119A (en) 2012-08-09 2022-08-26 细胞基因公司 Treatment of immune-related and inflammatory diseases
TR201904785T4 (en) 2012-08-09 2019-05-21 Celgene Corp A SOLID FORM OF (S) -3- (4 - ((4-MORPHOLINOMETHYL) BENZYL) OXY) -1-OXOISOINDOLIN-2-yl) PIPERIDINE-2,6-DIONE HYDROCHLORIDE.
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
US9156799B2 (en) 2012-09-07 2015-10-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
KR102229478B1 (en) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Treatment of cancers using pi3 kinase isoform modulators
US20150272924A1 (en) 2012-11-08 2015-10-01 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
US20140140952A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
EP2920195A1 (en) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
AU2013352106B2 (en) 2012-11-30 2018-04-26 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CA2895829A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
ES2834638T3 (en) 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Cancer treatment using PI3 kinase isoform modulators
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CN105683182A (en) 2013-08-30 2016-06-15 埃姆比特生物科学公司 Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (en) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc HETEROCYCLIC COMPOUNDS AND USES OF THEM
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
BR112016011949A8 (pt) 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
TWI705967B (en) 2014-03-20 2020-10-01 美商卡佩拉醫療公司 Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
CA3175724C (en) 2014-03-20 2024-01-09 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
WO2015157559A2 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins for the treatment of pain
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3142649B1 (en) 2014-05-12 2019-07-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitor emricasan
AU2015265607A1 (en) 2014-05-28 2016-11-17 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
MY186839A (en) 2014-06-19 2021-08-25 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
JP2017526713A (en) 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド Senicribiroc combination therapy to treat fibrosis
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR102331856B1 (en) 2014-10-21 2021-11-29 다케다 야쿠힌 고교 가부시키가이샤 Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
HUE049801T2 (en) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopyrazole kinase inhibitors
CN113149982A (en) 2015-01-20 2021-07-23 Xoc制药股份有限公司 Ergoline compounds and uses thereof
BR112017015510A2 (en) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc compound of formula (i), method of treatment and / or prevention, d2 receptor agonizing method in one individual, d3 receptor antagonizing method in one individual, 5-ht1d receptor agonizing method in one individual, 5-ht1a receptor agonization in one individual, selective 5-ht1d receptor agonizing method instead of 5-ht1b receptor in one individual, 5-ht2c re-receptor selective agonizing method instead of 5-ht2a or 5 receptor -ht2b in one individual, method of 5-ht2c receptor agonization in one individual, method of providing functional antagonist activity at 5-ht2b receptor or 5-ht7 receptor, and, method of providing functional antagonist activity at adrenergic receptors in one individual
HK1252245A1 (en) 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
WO2016210180A2 (en) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
EA201890512A1 (en) 2015-08-17 2018-09-28 Кура Онколоджи, Инк. METHODS OF TREATING PATIENTS WITH MALIGNANT TUMORS WITH THE USE OF PHARNESILTRANSFERASE INHIBITORS
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10112953B2 (en) 2015-09-30 2018-10-30 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
IL284874B2 (en) 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
EP4455145A3 (en) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
LT3394057T (en) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. SYNTHETIC METHOD FOR THE PRODUCTION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1-A ]ISOCHINOLIN-2-YLO 2-AMINO-3-METHYLBUTANOATO DI(4-METHYL BENZENESULFONATE)
EP3397251A1 (en) 2015-12-31 2018-11-07 Conatus Pharmaceuticals, Inc. Methods of using caspase inhibitors in treatment of liver disease
MX385964B (en) 2016-01-08 2025-03-18 Celgene Corp Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
KR20180095094A (en) 2016-01-08 2018-08-24 셀진 코포레이션 The use of biomarkers as predictors of clinical susceptibility to treatment methods and therapies for cancer
EP3399978B1 (en) 2016-01-08 2020-09-09 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
ES2912921T3 (en) 2016-04-29 2022-05-30 Fgh Biotech Inc Disubstituted pyrazole compounds for the treatment of diseases
TWI753910B (en) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11339142B2 (en) 2016-09-07 2022-05-24 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
MX390121B (en) 2016-09-19 2025-03-20 Mei Pharma Inc COMBINATIONS OF A BTK INHIBITOR AND A PI3K INHIBITOR FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES.
RS61745B1 (en) 2016-11-03 2021-05-31 Kura Oncology Inc Farnesyltransferase inhibitors for use in treating cancer
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
JP7105774B2 (en) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド Methods for treating cancer
TW202345829A (en) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 Use of valbenazine for treating schizophrenia or schizoaffective disorder
KR20230169457A (en) 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 Methods for the administration of certain vmat2 inhibitors
KR102003179B1 (en) 2017-02-21 2019-07-23 쿠라 온콜로지, 인크. Treatment of Cancer Patients Using Paranesyltransferase Inhibitors
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
EP3601326A4 (en) 2017-03-20 2020-12-16 The Broad Institute, Inc. COMPOUNDS AND PROCEDURES FOR REGULATING INSULIN SECRETION
CA3057978A1 (en) 2017-03-27 2018-10-04 The Regents Of The University Of California Compositions and method of treating cancer
EP3601290B1 (en) 2017-03-29 2021-11-24 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CN110831945B (en) 2017-03-29 2023-08-08 赛特温治疗公司 11, 13-modified saxitoxins for the treatment of pain
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (en) 2017-05-09 2019-09-22 Cardix Therapeutics LLC Pharmaceutical compositions and methods of treating cardiovascular diseases
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CA3063535A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
MA49141A (en) 2017-05-19 2020-03-25 Nflection Therapeutics Inc PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
JP2020522504A (en) 2017-06-01 2020-07-30 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ Polycyclic compounds and their uses
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (en) 2017-08-07 2020-03-20 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors.
RS66714B1 (en) 2017-09-21 2025-05-30 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
CA3076920A1 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California Immunomodulatory oligosaccharides
MX2020003421A (en) 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors.
KR20250070134A (en) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 Methods for the administration of certain vmat2 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
EP3814327A1 (en) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
MA53239A (en) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3873469A2 (en) 2018-11-01 2021-09-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3120351A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
MA55141A (en) 2018-11-20 2021-09-29 Nflection Therapeutics Inc CYANOARYL-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
EP4233834A3 (en) 2018-11-20 2023-10-25 NFlection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
US20220071941A1 (en) 2018-12-21 2022-03-10 Kura Oncology, Inc. Therapies for squamous cell carcinomas
TWI839461B (en) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a modulators and uses thereof
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020181165A1 (en) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
AU2020311404A1 (en) 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
AU2020310190A1 (en) 2019-07-11 2022-02-24 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP4003314B1 (en) 2019-07-26 2024-07-10 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP7566889B2 (en) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド IL-17A MODULATORS AND USES THEREOF
EP4034236A1 (en) 2019-09-26 2022-08-03 Abionyx Pharma SA Compounds useful for treating liver diseases
IL291398B2 (en) 2019-10-01 2025-05-01 Molecular Skin Therapeutics Inc Benzoxazinone compounds as klk5/7 dual inhibitors
EP4157271A1 (en) 2020-05-29 2023-04-05 Boulder Bioscience LLC Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4149471A4 (en) 2020-06-30 2024-07-10 Prosetta Biosciences, Inc. ISOQUINOLINE DERIVATIVES, THEIR SYNTHESIS PROCESSES AND THEIR USES
CN116368139A (en) 2020-08-14 2023-06-30 赛特温治疗公司 Nonhydrated ketone inhibitors of NAV1.7 for the treatment of pain
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
AU2022368836A1 (en) 2021-10-22 2024-05-02 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
MX2024005822A (en) 2021-11-30 2024-05-28 Kura Oncology Inc MACROCYCLIC COMPOUNDS WITH FARNESYLTRANSFERASE INHIBITORY ACTIVITY.
JP2025501308A (en) 2022-01-03 2025-01-17 ライラック セラピューティクス， インク． Acyclic Thiol Prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
JP2025507621A (en) 2022-03-02 2025-03-21 ミトパワー， インク． Novel prodrugs derived from nicotinic acid and ribose.
AU2023241822A1 (en) 2022-03-28 2024-09-26 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
AR129053A1 (en) 2022-04-14 2024-07-10 Bristol Myers Squibb Co NEW GSPT1 COMPOUNDS AND METHODS OF USING THE NEW COMPOUNDS
KR20250006012A (en) 2022-04-15 2025-01-10 셀진 코포레이션 Methods for predicting the responsiveness of lymphoma to drugs and methods for treating lymphoma
GEAP202516637A (en) 2022-04-25 2025-03-25 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
AU2023265665A1 (en) 2022-05-05 2024-10-10 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
JP2025531869A (en) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド CK1α and dual CK1α/GSPT1 degrading compounds
EP4593826A1 (en) 2022-09-30 2025-08-06 Boulder Bioscience LLC Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
EP4605084A2 (en) 2022-10-18 2025-08-27 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment
EP4608838A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
EP4626864A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024145662A1 (en) 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
TW202448485A (en) 2023-05-05 2024-12-16 美商拜奧馬林製藥公司 Dystrophin exon skipping oligonucleotides
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
IL327069A (en) 2023-09-27 2026-05-01 Isosterix Inc Myst inhibitors
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025085878A1 (en) 2023-10-20 2025-04-24 Altay Therapeutics, Inc. N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders
WO2025102082A1 (en) 2023-11-10 2025-05-15 Altay Therapeutics, Inc. Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025221809A1 (en) 2024-04-16 2025-10-23 Eluciderm Inc. 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
TW202604501A (en) 2024-05-17 2026-02-01 美商賽特溫治療公司 Substituted cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568536A (en) 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4650665A (en) 1985-02-08 1987-03-17 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
JPS6357533A (en) * 1986-08-26 1988-03-12 Taki Chem Co Ltd Sustained release base
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5271945A (en) 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP3116311B2 (en) 1990-06-13 2000-12-11 エーザイ株式会社 Manufacturing method of microsphere
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
JP3372558B2 (en) * 1990-09-14 2003-02-04 中外製薬株式会社 Microcapsule type sustained-release preparation and production method thereof
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
EP0630234B1 (en) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
DE4223169C1 (en) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Process for the microencapsulation of water-soluble active substances
DK0674506T3 (en) 1992-12-02 2001-01-08 Alkermes Inc Controlled release growth hormone-containing microspheres
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
WO1996040072A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US6204247B1 (en) 1997-08-15 2001-03-20 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US6770746B2 (en) 1997-08-15 2004-08-03 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US6420340B2 (en) 1997-08-15 2002-07-16 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
EP0905143A3 (en) * 1997-09-26 2000-09-06 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc and use
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
US6429296B2 (en) 1997-09-26 2002-08-06 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc and use
US6589547B1 (en) * 1998-03-04 2003-07-08 Takeda Chemical Industries, Ltd. Sustained-release preparation for AII antagonist, production and use thereof
US6482864B1 (en) * 1998-03-20 2002-11-19 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
WO1999048519A1 (en) * 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
AU744354B2 (en) * 1998-03-20 2002-02-21 Takeda Chemical Industries Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6979674B1 (en) 1998-12-23 2005-12-27 Amgen Inc. Polyol/oil suspensions for the sustained release of proteins
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6723347B1 (en) 1999-09-17 2004-04-20 Takeda Chemical Industries, Ltd. Proces for producing protein powder
WO2001030320A1 (en) * 1999-10-22 2001-05-03 Amgen Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
EP1258254A4 (en) * 2000-02-21 2004-02-04 Takeda Chemical Industries Ltd SLOW-RELEASE PREPARATIONS CONTAINING A PHYSIOLOGICALLY ACTIVE COMPOUND, NOT SO SOLUBLE IN WATER, AND METHOD OF PRODUCING AND USING THE SAME
US7090869B2 (en) 2000-12-01 2006-08-15 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
WO2002043709A1 (en) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Method for producing preparation containing bioactive substance
EP2062593A2 (en) 2000-12-01 2009-05-27 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive peptide
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
US7452860B2 (en) 2001-03-23 2008-11-18 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US7696162B2 (en) 2001-03-23 2010-04-13 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US7476652B2 (en) 2002-06-18 2009-01-13 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US7713930B2 (en) 2002-06-18 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US9376479B2 (en) 2002-12-31 2016-06-28 Anjinomoto Althea, Inc. Human growth hormone crystals and methods for preparing them
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US12558307B2 (en) 2009-07-06 2026-02-24 Sanofi-Aventis Insulin preparations containing methionine
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US12303598B2 (en) 2009-11-13 2025-05-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US11535659B2 (en) 2010-09-28 2022-12-27 Amryt Pharmaceuticals Inc. Engineered polypeptides having enhanced duration of action
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US12186374B2 (en) 2014-12-12 2025-01-07 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Also Published As

Publication number Publication date
AR005275A1 (en) 1999-04-28
CA2224381A1 (en) 1997-01-16
EP0835101A2 (en) 1998-04-15
AU6242096A (en) 1997-01-30
WO1997001331A3 (en) 1997-02-27
US6267981B1 (en) 2001-07-31
DE69632684D1 (en) 2004-07-15
ATE268591T1 (en) 2004-06-15
EP0835101B1 (en) 2004-06-09
JP2008273982A (en) 2008-11-13
DE69632684T2 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
EP0835101B1 (en) Method of producing sustained-release preparation
CA2127317C (en) Method of producing sustained-release preparation
CA2196184C (en) Sustained release preparation containing metal salt of a peptide
US6399103B1 (en) Method of producing a sustained-release preparation
EP0889722B1 (en) Sustained-release preparation and its production
CA2433037C (en) Sustained-release preparation
US20090142399A1 (en) Dispersant agent for sustained-release preparations
JP2002255857A (en) Sustained release preparation
EP1061948B1 (en) Sustained-release preparation of physiologically active polypeptide and production thereof
JP3862304B2 (en) Sustained release formulation
JPH107583A (en) Production of sustained-release preparation
JP4117922B2 (en) Sustained release preparation and production method thereof
JP4459315B2 (en) Manufacturing method of sustained-release preparation
JP3761594B2 (en) Manufacturing method of sustained-release preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996921094

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2224381

Country of ref document: CA

Ref country code: CA

Ref document number: 2224381

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996921094

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996921094

Country of ref document: EP